<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.0.6 on 08-Aug-2013 [07:18:47] {PM} EST - www.datatracks.com -->
<!-- Based on XBRL 2.1 -->
<xbrli:xbrl xmlns:tgtx="http://www.tgtherapeuticsinc.com/20130630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr">
  <link:schemaRef xlink:type="simple" xlink:href="tgtx-20130630.xsd" />

<!--Context Section-->
  <xbrli:context id="P01_01_2012To06_30_2012">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To06_30_2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2012To06_30_2012">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-04-01</xbrli:startDate>

      <xbrli:endDate>2012-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2013To06_30_2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-04-01</xbrli:startDate>

      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn07_29_2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-07-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P12_01_2011To06_30_2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-12-01</xbrli:startDate>

      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2011">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn11_30_2011">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2012">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

<!--Dimension Section-->
  <xbrli:context id="P01_01_2013To06_30_2013_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To06_30_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To06_30_2013_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2013To07_18_2013_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>

      <xbrli:endDate>2013-07-18</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn07_18_2013_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-07-18</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2009To03_31_2010_ManhattanAndAristonPharmaceuticalsMergerMembertgtxTypeOfTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tgtx:TypeOfTransactionAxis">tgtx:ManhattanAndAristonPharmaceuticalsMergerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2009-04-01</xbrli:startDate>

      <xbrli:endDate>2010-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2010_ManhattanAndAristonPharmaceuticalsMergerMembertgtxTypeOfTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tgtx:TypeOfTransactionAxis">tgtx:ManhattanAndAristonPharmaceuticalsMergerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2010-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2013_ManhattanAndAristonPharmaceuticalsMergerMembertgtxTypeOfTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tgtx:TypeOfTransactionAxis">tgtx:ManhattanAndAristonPharmaceuticalsMergerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2013_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2013_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2013_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2013_EquityIncentivePlansMemberusgaapPlanNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tgtx:EquityIncentivePlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2013_RestrictedStockMemberusgaapPlanNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To06_30_2013_RestrictedStockMemberusgaapPlanNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2013_CorporateMilestoneMembertgtxCorporateMilestoneAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tgtx:CorporateMilestoneAxis">tgtx:CorporateMilestoneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2013_NonEmployeeRestrictedStockMembertgtxNonEmployeeStockOptionsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tgtx:NonEmployeeStockOptionsAxis">tgtx:NonEmployeeRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To06_30_2013_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To06_30_2013_RestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_08_2010_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2010-03-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2010To03_08_2010_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-03-01</xbrli:startDate>

      <xbrli:endDate>2010-03-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_08_2010_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tgtx:IconClinicalResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2010-03-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2010To03_08_2010_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tgtx:IconClinicalResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-03-01</xbrli:startDate>

      <xbrli:endDate>2010-03-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2011_AfterAmendmentMembertgtxAmendmentAxis_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tgtx:AmendmentAxis">tgtx:AfterAmendmentMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tgtx:IconClinicalResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2011_BeforeAmendmentMembertgtxAmendmentAxis_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tgtx:AmendmentAxis">tgtx:BeforeAmendmentMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tgtx:IconClinicalResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2011_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tgtx:IconClinicalResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To06_30_2013_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tgtx:IconClinicalResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2013_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tgtx:IconClinicalResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2013_ConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">tgtx:ConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2013_IconConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">tgtx:IconConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_ConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">tgtx:ConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_IconConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">tgtx:IconConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To01_30_2012_LfbGroupMembertgtxPlacementAgencyAgreementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tgtx:PlacementAgencyAgreementAxis">tgtx:LfbGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-01-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To06_30_2013_LfbGroupMembertgtxPlacementAgencyAgreementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tgtx:PlacementAgencyAgreementAxis">tgtx:LfbGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2013_LfbGroupMembertgtxPlacementAgencyAgreementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tgtx:PlacementAgencyAgreementAxis">tgtx:LfbGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2013_ResearchDevelopmentExpensesMembertgtxResearchDevelopmentExpensesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tgtx:ResearchDevelopmentExpensesAxis">tgtx:ResearchDevelopmentExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn01_30_2012_LfbGroupMembertgtxPlacementAgencyAgreementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tgtx:PlacementAgencyAgreementAxis">tgtx:LfbGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-01-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_TreasuryStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_PreferredStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2013_PreferredStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2013_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2013_TreasuryStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2013_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_ContingentlyIssuableShareMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tgtx:ContingentlyIssuableShareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2013_ContingentlyIssuableShareMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tgtx:ContingentlyIssuableShareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_RestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2013_RestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:unit id="shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>

  <xbrli:unit id="USD_per_Share">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>

      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>

  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>

  <xbrli:unit id="pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>

<!--Element Section-->
  <dei:DocumentType contextRef="P01_01_2013To06_30_2013" id="Factid_1">10-Q</dei:DocumentType>

  <dei:AmendmentFlag contextRef="P01_01_2013To06_30_2013" id="Factid_2">false</dei:AmendmentFlag>

  <dei:DocumentPeriodEndDate contextRef="P01_01_2013To06_30_2013" id="Factid_3">2013-06-30</dei:DocumentPeriodEndDate>

  <dei:DocumentFiscalYearFocus contextRef="P01_01_2013To06_30_2013" id="Factid_4">2013</dei:DocumentFiscalYearFocus>

  <dei:DocumentFiscalPeriodFocus contextRef="P01_01_2013To06_30_2013" id="Factid_5">Q2</dei:DocumentFiscalPeriodFocus>

  <dei:TradingSymbol contextRef="P01_01_2013To06_30_2013" id="Factid_6">TGTX</dei:TradingSymbol>

  <dei:EntityCommonStockSharesOutstanding contextRef="PAsOn07_29_2013" id="Factid_7" unitRef="shares" decimals="INF">33276940</dei:EntityCommonStockSharesOutstanding>

  <dei:EntityRegistrantName contextRef="P01_01_2013To06_30_2013" id="Factid_8">TG THERAPEUTICS, INC.</dei:EntityRegistrantName>

  <dei:EntityCentralIndexKey contextRef="P01_01_2013To06_30_2013" id="Factid_9">0001001316</dei:EntityCentralIndexKey>

  <dei:CurrentFiscalYearEndDate contextRef="P01_01_2013To06_30_2013" id="Factid_10">--12-31</dei:CurrentFiscalYearEndDate>

  <dei:EntityFilerCategory contextRef="P01_01_2013To06_30_2013" id="Factid_11">Smaller Reporting Company</dei:EntityFilerCategory>

  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="PAsOn06_30_2013" id="Factid_12" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>

  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="PAsOn12_31_2012" id="Factid_13" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>

  <us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn06_30_2013" id="Factid_14" unitRef="shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>

  <us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn12_31_2012" id="Factid_15" unitRef="shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>

  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn06_30_2013" id="Factid_16" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>

  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn12_31_2012" id="Factid_17" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>

  <us-gaap:CommonStockSharesAuthorized contextRef="PAsOn06_30_2013" id="Factid_18" unitRef="shares" decimals="INF">500000000</us-gaap:CommonStockSharesAuthorized>

  <us-gaap:CommonStockSharesAuthorized contextRef="PAsOn12_31_2012" id="Factid_19" unitRef="shares" decimals="INF">500000000</us-gaap:CommonStockSharesAuthorized>

  <us-gaap:CommonStockSharesIssued contextRef="PAsOn06_30_2013" id="Factid_20" unitRef="shares" decimals="INF">26735466</us-gaap:CommonStockSharesIssued>

  <us-gaap:CommonStockSharesOutstanding contextRef="PAsOn06_30_2013" id="Factid_21" unitRef="shares" decimals="INF">26721940</us-gaap:CommonStockSharesOutstanding>

  <us-gaap:CommonStockSharesOutstanding contextRef="PAsOn12_31_2012" id="Factid_22" unitRef="shares" decimals="INF">25807212</us-gaap:CommonStockSharesOutstanding>

  <us-gaap:CommonStockSharesIssued contextRef="PAsOn12_31_2012" id="Factid_23" unitRef="shares" decimals="INF">25820738</us-gaap:CommonStockSharesIssued>

  <us-gaap:TreasuryStockShares contextRef="PAsOn06_30_2013" id="Factid_24" unitRef="shares" decimals="INF">13526</us-gaap:TreasuryStockShares>

  <us-gaap:TreasuryStockShares contextRef="PAsOn12_31_2012" id="Factid_25" unitRef="shares" decimals="INF">13526</us-gaap:TreasuryStockShares>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn06_30_2013" id="Factid_26" unitRef="USD" decimals="0">13416952</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2012" id="Factid_27" unitRef="USD" decimals="0">16455995</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <tgtx:PrepaidResearchAndDevelopment contextRef="PAsOn06_30_2013" id="Factid_28" unitRef="USD" decimals="0">615331</tgtx:PrepaidResearchAndDevelopment>

  <tgtx:PrepaidResearchAndDevelopment contextRef="PAsOn12_31_2012" id="Factid_29" unitRef="USD" decimals="0">1990759</tgtx:PrepaidResearchAndDevelopment>

  <us-gaap:OtherAssetsCurrent contextRef="PAsOn06_30_2013" id="Factid_30" unitRef="USD" decimals="0">136712</us-gaap:OtherAssetsCurrent>

  <us-gaap:OtherAssetsCurrent contextRef="PAsOn12_31_2012" id="Factid_31" unitRef="USD" decimals="0">29128</us-gaap:OtherAssetsCurrent>

  <us-gaap:AssetsCurrent contextRef="PAsOn06_30_2013" id="Factid_32" unitRef="USD" decimals="0">14168995</us-gaap:AssetsCurrent>

  <us-gaap:AssetsCurrent contextRef="PAsOn12_31_2012" id="Factid_33" unitRef="USD" decimals="0">18475882</us-gaap:AssetsCurrent>

  <us-gaap:PropertyPlantAndEquipmentNet contextRef="PAsOn06_30_2013" id="Factid_34" unitRef="USD" decimals="0">2527</us-gaap:PropertyPlantAndEquipmentNet>

  <us-gaap:PropertyPlantAndEquipmentNet contextRef="PAsOn12_31_2012" id="Factid_35" unitRef="USD" decimals="0">1164</us-gaap:PropertyPlantAndEquipmentNet>

  <tgtx:InProcessResearchAndDevelopment contextRef="PAsOn06_30_2013" id="Factid_36" unitRef="USD" decimals="0">2797600</tgtx:InProcessResearchAndDevelopment>

  <tgtx:InProcessResearchAndDevelopment contextRef="PAsOn12_31_2012" id="Factid_37" unitRef="USD" decimals="0">2797600</tgtx:InProcessResearchAndDevelopment>

  <us-gaap:Goodwill contextRef="PAsOn06_30_2013" id="Factid_38" unitRef="USD" decimals="0">799391</us-gaap:Goodwill>

  <us-gaap:Goodwill contextRef="PAsOn12_31_2012" id="Factid_39" unitRef="USD" decimals="0">799391</us-gaap:Goodwill>

  <us-gaap:Assets contextRef="PAsOn06_30_2013" id="Factid_40" unitRef="USD" decimals="0">17858571</us-gaap:Assets>

  <us-gaap:Assets contextRef="PAsOn12_31_2012" id="Factid_41" unitRef="USD" decimals="0">22074037</us-gaap:Assets>

  <us-gaap:NotesPayableCurrent contextRef="PAsOn06_30_2013" id="Factid_42" unitRef="USD" decimals="0">677778</us-gaap:NotesPayableCurrent>

  <us-gaap:NotesPayableCurrent contextRef="PAsOn12_31_2012" id="Factid_43" unitRef="USD" decimals="0">677778</us-gaap:NotesPayableCurrent>

  <us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="PAsOn06_30_2013" id="Factid_44" unitRef="USD" decimals="0">2247518</us-gaap:OtherAccountsPayableAndAccruedLiabilities>

  <us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="PAsOn12_31_2012" id="Factid_45" unitRef="USD" decimals="0">1117397</us-gaap:OtherAccountsPayableAndAccruedLiabilities>

  <us-gaap:DeferredCompensationLiabilityCurrent contextRef="PAsOn06_30_2013" id="Factid_46" unitRef="USD" decimals="0">232750</us-gaap:DeferredCompensationLiabilityCurrent>

  <us-gaap:DeferredCompensationLiabilityCurrent contextRef="PAsOn12_31_2012" id="Factid_47" unitRef="USD" decimals="0">145000</us-gaap:DeferredCompensationLiabilityCurrent>

  <us-gaap:DeferredRevenueCurrent contextRef="PAsOn06_30_2013" id="Factid_48" unitRef="USD" decimals="0">152381</us-gaap:DeferredRevenueCurrent>

  <us-gaap:DeferredRevenueCurrent contextRef="PAsOn12_31_2012" id="Factid_49" unitRef="USD" decimals="0">152381</us-gaap:DeferredRevenueCurrent>

  <us-gaap:InterestPayableCurrent contextRef="PAsOn06_30_2013" id="Factid_50" unitRef="USD" decimals="0">155829</us-gaap:InterestPayableCurrent>

  <us-gaap:InterestPayableCurrent contextRef="PAsOn12_31_2012" id="Factid_51" unitRef="USD" decimals="0">123511</us-gaap:InterestPayableCurrent>

  <us-gaap:LiabilitiesCurrent contextRef="PAsOn06_30_2013" id="Factid_52" unitRef="USD" decimals="0">3466256</us-gaap:LiabilitiesCurrent>

  <us-gaap:LiabilitiesCurrent contextRef="PAsOn12_31_2012" id="Factid_53" unitRef="USD" decimals="0">2216067</us-gaap:LiabilitiesCurrent>

  <us-gaap:DeferredRevenueNoncurrent contextRef="PAsOn06_30_2013" id="Factid_54" unitRef="USD" decimals="0">1752381</us-gaap:DeferredRevenueNoncurrent>

  <us-gaap:DeferredRevenueNoncurrent contextRef="PAsOn12_31_2012" id="Factid_55" unitRef="USD" decimals="0">1828571</us-gaap:DeferredRevenueNoncurrent>

  <us-gaap:LongTermNotesPayable contextRef="PAsOn06_30_2013" id="Factid_56" unitRef="USD" decimals="0">2364816</us-gaap:LongTermNotesPayable>

  <us-gaap:LongTermNotesPayable contextRef="PAsOn12_31_2012" id="Factid_57" unitRef="USD" decimals="0">2479098</us-gaap:LongTermNotesPayable>

  <us-gaap:Liabilities contextRef="PAsOn06_30_2013" id="Factid_58" unitRef="USD" decimals="0">7583453</us-gaap:Liabilities>

  <us-gaap:Liabilities contextRef="PAsOn12_31_2012" id="Factid_59" unitRef="USD" decimals="0">6523736</us-gaap:Liabilities>

  <us-gaap:PreferredStockValue contextRef="PAsOn06_30_2013" id="Factid_60" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>

  <us-gaap:PreferredStockValue contextRef="PAsOn12_31_2012" id="Factid_61" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>

  <us-gaap:CommonStockValue contextRef="PAsOn06_30_2013" id="Factid_62" unitRef="USD" decimals="0">26735</us-gaap:CommonStockValue>

  <us-gaap:CommonStockValue contextRef="PAsOn12_31_2012" id="Factid_63" unitRef="USD" decimals="0">25821</us-gaap:CommonStockValue>

  <tgtx:ContingentlyIssuableShares contextRef="PAsOn06_30_2013" id="Factid_64" unitRef="USD" decimals="0">6</tgtx:ContingentlyIssuableShares>

  <tgtx:ContingentlyIssuableShares contextRef="PAsOn12_31_2012" id="Factid_65" unitRef="USD" decimals="0">6</tgtx:ContingentlyIssuableShares>

  <us-gaap:AdditionalPaidInCapital contextRef="PAsOn06_30_2013" id="Factid_66" unitRef="USD" decimals="0">39516871</us-gaap:AdditionalPaidInCapital>

  <us-gaap:AdditionalPaidInCapital contextRef="PAsOn12_31_2012" id="Factid_67" unitRef="USD" decimals="0">34534805</us-gaap:AdditionalPaidInCapital>

  <us-gaap:TreasuryStockValue contextRef="PAsOn06_30_2013" id="Factid_68" unitRef="USD" decimals="0">84538</us-gaap:TreasuryStockValue>

  <us-gaap:TreasuryStockValue contextRef="PAsOn12_31_2012" id="Factid_69" unitRef="USD" decimals="0">84538</us-gaap:TreasuryStockValue>

  <us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage contextRef="PAsOn06_30_2013" id="Factid_70" unitRef="USD" decimals="0">29183956</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>

  <us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage contextRef="PAsOn12_31_2012" id="Factid_71" unitRef="USD" decimals="0">18925793</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn06_30_2013" id="Factid_72" unitRef="USD" decimals="0">10275118</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2012" id="Factid_73" unitRef="USD" decimals="0">15550301</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="PAsOn06_30_2013" id="Factid_74" unitRef="USD" decimals="0">17858571</us-gaap:LiabilitiesAndStockholdersEquity>

  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="PAsOn12_31_2012" id="Factid_75" unitRef="USD" decimals="0">22074037</us-gaap:LiabilitiesAndStockholdersEquity>

  <us-gaap:OtherAssetsNoncurrent contextRef="PAsOn06_30_2013" id="Factid_76" unitRef="USD" decimals="0">90058</us-gaap:OtherAssetsNoncurrent>

  <us-gaap:OtherAssetsNoncurrent contextRef="PAsOn12_31_2012" id="Factid_77" unitRef="USD" decimals="0">0</us-gaap:OtherAssetsNoncurrent>

  <us-gaap:CommitmentsAndContingencies contextRef="PAsOn06_30_2013" id="Factid_78" unitRef="USD" xsi:nil="true" />

  <us-gaap:CommitmentsAndContingencies contextRef="PAsOn12_31_2012" id="Factid_79" unitRef="USD" xsi:nil="true" />

  <us-gaap:LicensesRevenue contextRef="P04_01_2013To06_30_2013" id="Factid_80" unitRef="USD" decimals="0">38095</us-gaap:LicensesRevenue>

  <us-gaap:LicensesRevenue contextRef="P04_01_2012To06_30_2012" id="Factid_81" unitRef="USD" decimals="0">0</us-gaap:LicensesRevenue>

  <us-gaap:LicensesRevenue contextRef="P01_01_2013To06_30_2013" id="Factid_82" unitRef="USD" decimals="0">76190</us-gaap:LicensesRevenue>

  <us-gaap:LicensesRevenue contextRef="P01_01_2012To06_30_2012" id="Factid_83" unitRef="USD" decimals="0">0</us-gaap:LicensesRevenue>

  <us-gaap:LicensesRevenue contextRef="P12_01_2011To06_30_2013" id="Factid_84" unitRef="USD" decimals="0">95238</us-gaap:LicensesRevenue>

  <tgtx:NonCashStockExpense contextRef="P04_01_2013To06_30_2013" id="Factid_85" unitRef="USD" decimals="0">0</tgtx:NonCashStockExpense>

  <tgtx:NonCashStockExpense contextRef="P04_01_2012To06_30_2012" id="Factid_86" unitRef="USD" decimals="0">0</tgtx:NonCashStockExpense>

  <tgtx:NonCashStockExpense contextRef="P01_01_2013To06_30_2013" id="Factid_87" unitRef="USD" decimals="0">0</tgtx:NonCashStockExpense>

  <tgtx:NonCashStockExpense contextRef="P01_01_2012To06_30_2012" id="Factid_88" unitRef="USD" decimals="0">16578000</tgtx:NonCashStockExpense>

  <tgtx:NonCashStockExpense contextRef="P12_01_2011To06_30_2013" id="Factid_89" unitRef="USD" decimals="0">16875000</tgtx:NonCashStockExpense>

  <tgtx:NonCashCompensationResearchAndDevelopmentExpenses contextRef="P04_01_2013To06_30_2013" id="Factid_90" unitRef="USD" decimals="0">366168</tgtx:NonCashCompensationResearchAndDevelopmentExpenses>

  <tgtx:NonCashCompensationResearchAndDevelopmentExpenses contextRef="P04_01_2012To06_30_2012" id="Factid_91" unitRef="USD" decimals="0">109198</tgtx:NonCashCompensationResearchAndDevelopmentExpenses>

  <tgtx:NonCashCompensationResearchAndDevelopmentExpenses contextRef="P01_01_2013To06_30_2013" id="Factid_92" unitRef="USD" decimals="0">720871</tgtx:NonCashCompensationResearchAndDevelopmentExpenses>

  <tgtx:NonCashCompensationResearchAndDevelopmentExpenses contextRef="P01_01_2012To06_30_2012" id="Factid_93" unitRef="USD" decimals="0">109198</tgtx:NonCashCompensationResearchAndDevelopmentExpenses>

  <tgtx:NonCashCompensationResearchAndDevelopmentExpenses contextRef="P12_01_2011To06_30_2013" id="Factid_94" unitRef="USD" decimals="0">1176680</tgtx:NonCashCompensationResearchAndDevelopmentExpenses>

  <tgtx:OtherResearchAndDevelopment contextRef="P04_01_2013To06_30_2013" id="Factid_95" unitRef="USD" decimals="0">4661455</tgtx:OtherResearchAndDevelopment>

  <tgtx:OtherResearchAndDevelopment contextRef="P04_01_2012To06_30_2012" id="Factid_96" unitRef="USD" decimals="0">1536896</tgtx:OtherResearchAndDevelopment>

  <tgtx:OtherResearchAndDevelopment contextRef="P01_01_2013To06_30_2013" id="Factid_97" unitRef="USD" decimals="0">5876657</tgtx:OtherResearchAndDevelopment>

  <tgtx:OtherResearchAndDevelopment contextRef="P01_01_2012To06_30_2012" id="Factid_98" unitRef="USD" decimals="0">1700249</tgtx:OtherResearchAndDevelopment>

  <tgtx:OtherResearchAndDevelopment contextRef="P12_01_2011To06_30_2013" id="Factid_99" unitRef="USD" decimals="0">9901122</tgtx:OtherResearchAndDevelopment>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P04_01_2013To06_30_2013" id="Factid_100" unitRef="USD" decimals="0">5027623</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P04_01_2012To06_30_2012" id="Factid_101" unitRef="USD" decimals="0">1646094</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P01_01_2013To06_30_2013" id="Factid_102" unitRef="USD" decimals="0">6597528</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P01_01_2012To06_30_2012" id="Factid_103" unitRef="USD" decimals="0">18387447</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P12_01_2011To06_30_2013" id="Factid_104" unitRef="USD" decimals="0">27952802</us-gaap:ResearchAndDevelopmentExpense>

  <tgtx:NonCashCompensationGeneralAndAdministrativeExpenses contextRef="P04_01_2013To06_30_2013" id="Factid_105" unitRef="USD" decimals="0">1007600</tgtx:NonCashCompensationGeneralAndAdministrativeExpenses>

  <tgtx:NonCashCompensationGeneralAndAdministrativeExpenses contextRef="P04_01_2012To06_30_2012" id="Factid_106" unitRef="USD" decimals="0">1062793</tgtx:NonCashCompensationGeneralAndAdministrativeExpenses>

  <tgtx:NonCashCompensationGeneralAndAdministrativeExpenses contextRef="P01_01_2013To06_30_2013" id="Factid_107" unitRef="USD" decimals="0">2538374</tgtx:NonCashCompensationGeneralAndAdministrativeExpenses>

  <tgtx:NonCashCompensationGeneralAndAdministrativeExpenses contextRef="P01_01_2012To06_30_2012" id="Factid_108" unitRef="USD" decimals="0">1251302</tgtx:NonCashCompensationGeneralAndAdministrativeExpenses>

  <tgtx:NonCashCompensationGeneralAndAdministrativeExpenses contextRef="P12_01_2011To06_30_2013" id="Factid_109" unitRef="USD" decimals="0">5591241</tgtx:NonCashCompensationGeneralAndAdministrativeExpenses>

  <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="P04_01_2013To06_30_2013" id="Factid_110" unitRef="USD" decimals="0">631637</us-gaap:OtherGeneralAndAdministrativeExpense>

  <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="P04_01_2012To06_30_2012" id="Factid_111" unitRef="USD" decimals="0">396043</us-gaap:OtherGeneralAndAdministrativeExpense>

  <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="P01_01_2013To06_30_2013" id="Factid_112" unitRef="USD" decimals="0">1283094</us-gaap:OtherGeneralAndAdministrativeExpense>

  <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="P01_01_2012To06_30_2012" id="Factid_113" unitRef="USD" decimals="0">851535</us-gaap:OtherGeneralAndAdministrativeExpense>

  <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="P12_01_2011To06_30_2013" id="Factid_114" unitRef="USD" decimals="0">3566374</us-gaap:OtherGeneralAndAdministrativeExpense>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P04_01_2013To06_30_2013" id="Factid_115" unitRef="USD" decimals="0">1639237</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P04_01_2012To06_30_2012" id="Factid_116" unitRef="USD" decimals="0">1458836</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P01_01_2013To06_30_2013" id="Factid_117" unitRef="USD" decimals="0">3821468</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P01_01_2012To06_30_2012" id="Factid_118" unitRef="USD" decimals="0">2102837</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P12_01_2011To06_30_2013" id="Factid_119" unitRef="USD" decimals="0">9157615</us-gaap:GeneralAndAdministrativeExpense>

  <tgtx:ImpairmentOfInProcessResearchAndDevelopment contextRef="P04_01_2013To06_30_2013" id="Factid_120" unitRef="USD" decimals="0">0</tgtx:ImpairmentOfInProcessResearchAndDevelopment>

  <tgtx:ImpairmentOfInProcessResearchAndDevelopment contextRef="P04_01_2012To06_30_2012" id="Factid_121" unitRef="USD" decimals="0">0</tgtx:ImpairmentOfInProcessResearchAndDevelopment>

  <tgtx:ImpairmentOfInProcessResearchAndDevelopment contextRef="P01_01_2013To06_30_2013" id="Factid_122" unitRef="USD" decimals="0">0</tgtx:ImpairmentOfInProcessResearchAndDevelopment>

  <tgtx:ImpairmentOfInProcessResearchAndDevelopment contextRef="P01_01_2012To06_30_2012" id="Factid_123" unitRef="USD" decimals="0">0</tgtx:ImpairmentOfInProcessResearchAndDevelopment>

  <tgtx:ImpairmentOfInProcessResearchAndDevelopment contextRef="P12_01_2011To06_30_2013" id="Factid_124" unitRef="USD" decimals="0">1104700</tgtx:ImpairmentOfInProcessResearchAndDevelopment>

  <us-gaap:OperatingExpenses contextRef="P04_01_2013To06_30_2013" id="Factid_125" unitRef="USD" decimals="0">6666860</us-gaap:OperatingExpenses>

  <us-gaap:OperatingExpenses contextRef="P04_01_2012To06_30_2012" id="Factid_126" unitRef="USD" decimals="0">3104930</us-gaap:OperatingExpenses>

  <us-gaap:OperatingExpenses contextRef="P01_01_2013To06_30_2013" id="Factid_127" unitRef="USD" decimals="0">10418996</us-gaap:OperatingExpenses>

  <us-gaap:OperatingExpenses contextRef="P01_01_2012To06_30_2012" id="Factid_128" unitRef="USD" decimals="0">20490284</us-gaap:OperatingExpenses>

  <us-gaap:OperatingExpenses contextRef="P12_01_2011To06_30_2013" id="Factid_129" unitRef="USD" decimals="0">38215117</us-gaap:OperatingExpenses>

  <us-gaap:OperatingIncomeLoss contextRef="P04_01_2013To06_30_2013" id="Factid_130" unitRef="USD" decimals="0">-6628765</us-gaap:OperatingIncomeLoss>

  <us-gaap:OperatingIncomeLoss contextRef="P04_01_2012To06_30_2012" id="Factid_131" unitRef="USD" decimals="0">-3104930</us-gaap:OperatingIncomeLoss>

  <us-gaap:OperatingIncomeLoss contextRef="P01_01_2013To06_30_2013" id="Factid_132" unitRef="USD" decimals="0">-10342806</us-gaap:OperatingIncomeLoss>

  <us-gaap:OperatingIncomeLoss contextRef="P01_01_2012To06_30_2012" id="Factid_133" unitRef="USD" decimals="0">-20490284</us-gaap:OperatingIncomeLoss>

  <us-gaap:OperatingIncomeLoss contextRef="P12_01_2011To06_30_2013" id="Factid_134" unitRef="USD" decimals="0">-38119879</us-gaap:OperatingIncomeLoss>

  <us-gaap:InvestmentIncomeNet contextRef="P04_01_2013To06_30_2013" id="Factid_135" unitRef="USD" decimals="0">1177</us-gaap:InvestmentIncomeNet>

  <us-gaap:InvestmentIncomeNet contextRef="P04_01_2012To06_30_2012" id="Factid_136" unitRef="USD" decimals="0">4092</us-gaap:InvestmentIncomeNet>

  <us-gaap:InvestmentIncomeNet contextRef="P01_01_2013To06_30_2013" id="Factid_137" unitRef="USD" decimals="0">2679</us-gaap:InvestmentIncomeNet>

  <us-gaap:InvestmentIncomeNet contextRef="P01_01_2012To06_30_2012" id="Factid_138" unitRef="USD" decimals="0">7760</us-gaap:InvestmentIncomeNet>

  <us-gaap:InvestmentIncomeNet contextRef="P12_01_2011To06_30_2013" id="Factid_139" unitRef="USD" decimals="0">18466</us-gaap:InvestmentIncomeNet>

  <us-gaap:OtherIncome contextRef="P04_01_2013To06_30_2013" id="Factid_140" unitRef="USD" decimals="0">0</us-gaap:OtherIncome>

  <us-gaap:OtherIncome contextRef="P04_01_2012To06_30_2012" id="Factid_141" unitRef="USD" decimals="0">272232</us-gaap:OtherIncome>

  <us-gaap:OtherIncome contextRef="P01_01_2013To06_30_2013" id="Factid_142" unitRef="USD" decimals="0">0</us-gaap:OtherIncome>

  <us-gaap:OtherIncome contextRef="P01_01_2012To06_30_2012" id="Factid_143" unitRef="USD" decimals="0">272232</us-gaap:OtherIncome>

  <us-gaap:OtherIncome contextRef="P12_01_2011To06_30_2013" id="Factid_144" unitRef="USD" decimals="0">272232</us-gaap:OtherIncome>

  <us-gaap:InterestExpense contextRef="P04_01_2013To06_30_2013" id="Factid_145" unitRef="USD" decimals="0">240014</us-gaap:InterestExpense>

  <us-gaap:InterestExpense contextRef="P04_01_2012To06_30_2012" id="Factid_146" unitRef="USD" decimals="0">228109</us-gaap:InterestExpense>

  <us-gaap:InterestExpense contextRef="P01_01_2013To06_30_2013" id="Factid_147" unitRef="USD" decimals="0">471486</us-gaap:InterestExpense>

  <us-gaap:InterestExpense contextRef="P01_01_2012To06_30_2012" id="Factid_148" unitRef="USD" decimals="0">448258</us-gaap:InterestExpense>

  <us-gaap:InterestExpense contextRef="P12_01_2011To06_30_2013" id="Factid_149" unitRef="USD" decimals="0">1384327</us-gaap:InterestExpense>

  <tgtx:ChangeInFairValueOfNonCurrentNotePayable contextRef="P04_01_2013To06_30_2013" id="Factid_150" unitRef="USD" decimals="0">283050</tgtx:ChangeInFairValueOfNonCurrentNotePayable>

  <tgtx:ChangeInFairValueOfNonCurrentNotePayable contextRef="P04_01_2012To06_30_2012" id="Factid_151" unitRef="USD" decimals="0">482556</tgtx:ChangeInFairValueOfNonCurrentNotePayable>

  <tgtx:ChangeInFairValueOfNonCurrentNotePayable contextRef="P01_01_2013To06_30_2013" id="Factid_152" unitRef="USD" decimals="0">553450</tgtx:ChangeInFairValueOfNonCurrentNotePayable>

  <tgtx:ChangeInFairValueOfNonCurrentNotePayable contextRef="P01_01_2012To06_30_2012" id="Factid_153" unitRef="USD" decimals="0">687853</tgtx:ChangeInFairValueOfNonCurrentNotePayable>

  <tgtx:ChangeInFairValueOfNonCurrentNotePayable contextRef="P12_01_2011To06_30_2013" id="Factid_154" unitRef="USD" decimals="0">2213322</tgtx:ChangeInFairValueOfNonCurrentNotePayable>

  <us-gaap:NonoperatingIncomeExpense contextRef="P04_01_2013To06_30_2013" id="Factid_155" unitRef="USD" decimals="0">44213</us-gaap:NonoperatingIncomeExpense>

  <us-gaap:NonoperatingIncomeExpense contextRef="P04_01_2012To06_30_2012" id="Factid_156" unitRef="USD" decimals="0">530771</us-gaap:NonoperatingIncomeExpense>

  <us-gaap:NonoperatingIncomeExpense contextRef="P01_01_2013To06_30_2013" id="Factid_157" unitRef="USD" decimals="0">84643</us-gaap:NonoperatingIncomeExpense>

  <us-gaap:NonoperatingIncomeExpense contextRef="P01_01_2012To06_30_2012" id="Factid_158" unitRef="USD" decimals="0">519587</us-gaap:NonoperatingIncomeExpense>

  <us-gaap:NonoperatingIncomeExpense contextRef="P12_01_2011To06_30_2013" id="Factid_159" unitRef="USD" decimals="0">1119693</us-gaap:NonoperatingIncomeExpense>

  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="P04_01_2013To06_30_2013" id="Factid_160" unitRef="USD" decimals="0">-6584552</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>

  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="P04_01_2012To06_30_2012" id="Factid_161" unitRef="USD" decimals="0">-2574159</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>

  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="P01_01_2013To06_30_2013" id="Factid_162" unitRef="USD" decimals="0">-10258163</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>

  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="P01_01_2012To06_30_2012" id="Factid_163" unitRef="USD" decimals="0">-19970697</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>

  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="P12_01_2011To06_30_2013" id="Factid_164" unitRef="USD" decimals="0">-37000186</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>

  <us-gaap:IncomeTaxExpenseBenefit contextRef="P04_01_2013To06_30_2013" id="Factid_165" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>

  <us-gaap:IncomeTaxExpenseBenefit contextRef="P04_01_2012To06_30_2012" id="Factid_166" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>

  <us-gaap:IncomeTaxExpenseBenefit contextRef="P01_01_2013To06_30_2013" id="Factid_167" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>

  <us-gaap:IncomeTaxExpenseBenefit contextRef="P01_01_2012To06_30_2012" id="Factid_168" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>

  <us-gaap:IncomeTaxExpenseBenefit contextRef="P12_01_2011To06_30_2013" id="Factid_169" unitRef="USD" decimals="0">330000</us-gaap:IncomeTaxExpenseBenefit>

  <us-gaap:ProfitLoss contextRef="P04_01_2013To06_30_2013" id="Factid_170" unitRef="USD" decimals="0">-6584552</us-gaap:ProfitLoss>

  <us-gaap:ProfitLoss contextRef="P04_01_2012To06_30_2012" id="Factid_171" unitRef="USD" decimals="0">-2574159</us-gaap:ProfitLoss>

  <us-gaap:ProfitLoss contextRef="P01_01_2013To06_30_2013" id="Factid_172" unitRef="USD" decimals="0">-10258163</us-gaap:ProfitLoss>

  <us-gaap:ProfitLoss contextRef="P01_01_2012To06_30_2012" id="Factid_173" unitRef="USD" decimals="0">-19970697</us-gaap:ProfitLoss>

  <us-gaap:ProfitLoss contextRef="P12_01_2011To06_30_2013" id="Factid_174" unitRef="USD" decimals="0">-37330186</us-gaap:ProfitLoss>

  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="P04_01_2013To06_30_2013" id="Factid_175" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>

  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="P04_01_2012To06_30_2012" id="Factid_176" unitRef="USD" decimals="0">-679506</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>

  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="P01_01_2013To06_30_2013" id="Factid_177" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>

  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="P01_01_2012To06_30_2012" id="Factid_178" unitRef="USD" decimals="0">-7819954</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>

  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="P12_01_2011To06_30_2013" id="Factid_179" unitRef="USD" decimals="0">-8146230</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2013To06_30_2013" id="Factid_180" unitRef="USD" decimals="0">-6584552</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P04_01_2012To06_30_2012" id="Factid_181" unitRef="USD" decimals="0">-1894653</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2013To06_30_2013" id="Factid_182" unitRef="USD" decimals="0">-10258163</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2012To06_30_2012" id="Factid_183" unitRef="USD" decimals="0">-12150743</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P12_01_2011To06_30_2013" id="Factid_184" unitRef="USD" decimals="0">-29183956</us-gaap:NetIncomeLoss>

  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="P04_01_2013To06_30_2013" id="Factid_185" unitRef="USD_per_Share" decimals="2">-0.29</us-gaap:EarningsPerShareBasicAndDiluted>

  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="P04_01_2012To06_30_2012" id="Factid_186" unitRef="USD_per_Share" decimals="2">-0.16</us-gaap:EarningsPerShareBasicAndDiluted>

  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="P01_01_2013To06_30_2013" id="Factid_187" unitRef="USD_per_Share" decimals="2">-0.46</us-gaap:EarningsPerShareBasicAndDiluted>

  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="P01_01_2012To06_30_2012" id="Factid_188" unitRef="USD_per_Share" decimals="2">-1.44</us-gaap:EarningsPerShareBasicAndDiluted>

  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P04_01_2012To06_30_2012" id="Factid_189" unitRef="shares" decimals="INF">11777563</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P01_01_2013To06_30_2013" id="Factid_190" unitRef="shares" decimals="INF">22213335</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P01_01_2012To06_30_2012" id="Factid_191" unitRef="shares" decimals="INF">8419481</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P04_01_2013To06_30_2013" id="Factid_192" unitRef="shares" decimals="INF">22483394</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2012_TreasuryStockMemberusgaapStatementEquityComponentsAxis" id="Factid_193" unitRef="USD" decimals="0">-84538</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2012_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_194" unitRef="USD" decimals="0">-18925793</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2012_PreferredStockMemberusgaapStatementEquityComponentsAxis" id="Factid_195" unitRef="USD" decimals="0">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_196" unitRef="USD" decimals="0">25821</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2012_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_197" unitRef="USD" decimals="0">34534805</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <tgtx:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2013To06_30_2013" id="Factid_198" unitRef="USD" decimals="0">1723736</tgtx:StockIssuedDuringPeriodValueExerciseOfWarrants>

  <tgtx:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2013To06_30_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_199" unitRef="USD" decimals="0">766</tgtx:StockIssuedDuringPeriodValueExerciseOfWarrants>

  <tgtx:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2013To06_30_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_200" unitRef="USD" decimals="0">1722970</tgtx:StockIssuedDuringPeriodValueExerciseOfWarrants>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2012_PreferredStockMemberusgaapStatementEquityComponentsAxis" id="Factid_201" unitRef="shares" decimals="INF">0</us-gaap:SharesOutstanding>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_202" unitRef="shares" decimals="INF">25820738</us-gaap:SharesOutstanding>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2012_TreasuryStockMemberusgaapStatementEquityComponentsAxis" id="Factid_203" unitRef="shares" decimals="INF">13526</us-gaap:SharesOutstanding>

  <tgtx:StockIssuedDuringPeriodSharesExerciseOfWarrants contextRef="P01_01_2013To06_30_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_204" unitRef="shares" decimals="INF">766105</tgtx:StockIssuedDuringPeriodSharesExerciseOfWarrants>

  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="P01_01_2013To06_30_2013" id="Factid_205" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>

  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="P01_01_2013To06_30_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_206" unitRef="USD" decimals="0">147</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>

  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="P01_01_2013To06_30_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_207" unitRef="USD" decimals="0">-147</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>

  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="P01_01_2013To06_30_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_208" unitRef="shares" decimals="INF">147044</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="P01_01_2013To06_30_2013" id="Factid_209" unitRef="USD" decimals="0">3259245</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="P01_01_2013To06_30_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_210" unitRef="USD" decimals="0">3259245</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>

  <us-gaap:ProfitLoss contextRef="P01_01_2013To06_30_2013_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_211" unitRef="USD" decimals="0">-10258163</us-gaap:ProfitLoss>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn06_30_2013_PreferredStockMemberusgaapStatementEquityComponentsAxis" id="Factid_212" unitRef="USD" decimals="0">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn06_30_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_213" unitRef="USD" decimals="0">26735</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn06_30_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_214" unitRef="USD" decimals="0">39516871</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn06_30_2013_TreasuryStockMemberusgaapStatementEquityComponentsAxis" id="Factid_215" unitRef="USD" decimals="0">-84538</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn06_30_2013_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_216" unitRef="USD" decimals="0">-29183956</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:SharesOutstanding contextRef="PAsOn06_30_2013_PreferredStockMemberusgaapStatementEquityComponentsAxis" id="Factid_217" unitRef="shares" decimals="INF">0</us-gaap:SharesOutstanding>

  <us-gaap:SharesOutstanding contextRef="PAsOn06_30_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_218" unitRef="shares" decimals="INF">26735466</us-gaap:SharesOutstanding>

  <us-gaap:SharesOutstanding contextRef="PAsOn06_30_2013_TreasuryStockMemberusgaapStatementEquityComponentsAxis" id="Factid_219" unitRef="shares" decimals="INF">13526</us-gaap:SharesOutstanding>

  <tgtx:StockIssuedDuringPeriodValueExerciseOfWarrantsCashLess contextRef="P01_01_2013To06_30_2013" id="Factid_220" unitRef="USD" decimals="0">-1</tgtx:StockIssuedDuringPeriodValueExerciseOfWarrantsCashLess>

  <tgtx:StockIssuedDuringPeriodValueExerciseOfWarrantsCashLess contextRef="P01_01_2013To06_30_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_221" unitRef="USD" decimals="0">1</tgtx:StockIssuedDuringPeriodValueExerciseOfWarrantsCashLess>

  <tgtx:StockIssuedDuringPeriodValueExerciseOfWarrantsCashLess contextRef="P01_01_2013To06_30_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_222" unitRef="USD" decimals="0">-2</tgtx:StockIssuedDuringPeriodValueExerciseOfWarrantsCashLess>

  <tgtx:StockIssuedDuringPeriodSharesExerciseOfWarrantsCashLess contextRef="P01_01_2013To06_30_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_223" unitRef="shares" decimals="INF">1579</tgtx:StockIssuedDuringPeriodSharesExerciseOfWarrantsCashLess>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2012_ContingentlyIssuableShareMemberusgaapStatementEquityComponentsAxis" id="Factid_224" unitRef="USD" decimals="0">6</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn06_30_2013_ContingentlyIssuableShareMemberusgaapStatementEquityComponentsAxis" id="Factid_225" unitRef="USD" decimals="0">6</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2013To06_30_2013" id="Factid_226" unitRef="USD" decimals="0">3259245</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2012To06_30_2012" id="Factid_227" unitRef="USD" decimals="0">1360500</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P12_01_2011To06_30_2013" id="Factid_228" unitRef="USD" decimals="0">6767921</us-gaap:ShareBasedCompensation>

  <tgtx:SharesIssuedInConnectionWithInLicensingAgreement contextRef="P01_01_2013To06_30_2013" id="Factid_229" unitRef="USD" decimals="0">0</tgtx:SharesIssuedInConnectionWithInLicensingAgreement>

  <tgtx:SharesIssuedInConnectionWithInLicensingAgreement contextRef="P01_01_2012To06_30_2012" id="Factid_230" unitRef="USD" decimals="0">16578000</tgtx:SharesIssuedInConnectionWithInLicensingAgreement>

  <tgtx:SharesIssuedInConnectionWithInLicensingAgreement contextRef="P12_01_2011To06_30_2013" id="Factid_231" unitRef="USD" decimals="0">16875000</tgtx:SharesIssuedInConnectionWithInLicensingAgreement>

  <us-gaap:Depreciation contextRef="P01_01_2013To06_30_2013" id="Factid_232" unitRef="USD" decimals="0">309</us-gaap:Depreciation>

  <us-gaap:Depreciation contextRef="P01_01_2012To06_30_2012" id="Factid_233" unitRef="USD" decimals="0">0</us-gaap:Depreciation>

  <us-gaap:Depreciation contextRef="P12_01_2011To06_30_2013" id="Factid_234" unitRef="USD" decimals="0">544</us-gaap:Depreciation>

  <tgtx:ChangeInFairValueOfNotesPayable contextRef="P01_01_2013To06_30_2013" id="Factid_235" unitRef="USD" decimals="0">114282</tgtx:ChangeInFairValueOfNotesPayable>

  <tgtx:ChangeInFairValueOfNotesPayable contextRef="P01_01_2012To06_30_2012" id="Factid_236" unitRef="USD" decimals="0">269597</tgtx:ChangeInFairValueOfNotesPayable>

  <tgtx:ChangeInFairValueOfNotesPayable contextRef="P12_01_2011To06_30_2013" id="Factid_237" unitRef="USD" decimals="0">929981</tgtx:ChangeInFairValueOfNotesPayable>

  <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="P01_01_2013To06_30_2013" id="Factid_238" unitRef="USD" decimals="0">-1267843</us-gaap:IncreaseDecreaseInOtherCurrentAssets>

  <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="P01_01_2012To06_30_2012" id="Factid_239" unitRef="USD" decimals="0">2313</us-gaap:IncreaseDecreaseInOtherCurrentAssets>

  <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="P12_01_2011To06_30_2013" id="Factid_240" unitRef="USD" decimals="0">661274</us-gaap:IncreaseDecreaseInOtherCurrentAssets>

  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="P01_01_2013To06_30_2013" id="Factid_241" unitRef="USD" decimals="0">32318</us-gaap:IncreaseDecreaseInInterestPayableNet>

  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="P01_01_2012To06_30_2012" id="Factid_242" unitRef="USD" decimals="0">30003</us-gaap:IncreaseDecreaseInInterestPayableNet>

  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="P12_01_2011To06_30_2013" id="Factid_243" unitRef="USD" decimals="0">100986</us-gaap:IncreaseDecreaseInInterestPayableNet>

  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="P01_01_2013To06_30_2013" id="Factid_244" unitRef="USD" decimals="0">1217871</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>

  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="P01_01_2012To06_30_2012" id="Factid_245" unitRef="USD" decimals="0">912685</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>

  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="P12_01_2011To06_30_2013" id="Factid_246" unitRef="USD" decimals="0">2221938</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>

  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="P01_01_2013To06_30_2013" id="Factid_247" unitRef="USD" decimals="0">-76190</us-gaap:IncreaseDecreaseInDeferredRevenue>

  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="P01_01_2012To06_30_2012" id="Factid_248" unitRef="USD" decimals="0">0</us-gaap:IncreaseDecreaseInDeferredRevenue>

  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="P12_01_2011To06_30_2013" id="Factid_249" unitRef="USD" decimals="0">1904762</us-gaap:IncreaseDecreaseInDeferredRevenue>

  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="P01_01_2013To06_30_2013" id="Factid_250" unitRef="USD" decimals="0">-4761107</us-gaap:NetCashProvidedByUsedInOperatingActivities>

  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="P01_01_2012To06_30_2012" id="Factid_251" unitRef="USD" decimals="0">-1361419</us-gaap:NetCashProvidedByUsedInOperatingActivities>

  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="P12_01_2011To06_30_2013" id="Factid_252" unitRef="USD" decimals="0">-10035648</us-gaap:NetCashProvidedByUsedInOperatingActivities>

  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="P01_01_2013To06_30_2013" id="Factid_253" unitRef="USD" decimals="0">1672</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="P01_01_2012To06_30_2012" id="Factid_254" unitRef="USD" decimals="0">1399</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="P12_01_2011To06_30_2013" id="Factid_255" unitRef="USD" decimals="0">3071</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

  <us-gaap:CashAcquiredFromAcquisition contextRef="P01_01_2013To06_30_2013" id="Factid_256" unitRef="USD" decimals="0">0</us-gaap:CashAcquiredFromAcquisition>

  <us-gaap:CashAcquiredFromAcquisition contextRef="P01_01_2012To06_30_2012" id="Factid_257" unitRef="USD" decimals="0">0</us-gaap:CashAcquiredFromAcquisition>

  <us-gaap:CashAcquiredFromAcquisition contextRef="P12_01_2011To06_30_2013" id="Factid_258" unitRef="USD" decimals="0">10386</us-gaap:CashAcquiredFromAcquisition>

  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="P01_01_2013To06_30_2013" id="Factid_259" unitRef="USD" decimals="0">-1672</us-gaap:NetCashProvidedByUsedInInvestingActivities>

  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="P01_01_2012To06_30_2012" id="Factid_260" unitRef="USD" decimals="0">-1399</us-gaap:NetCashProvidedByUsedInInvestingActivities>

  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="P12_01_2011To06_30_2013" id="Factid_261" unitRef="USD" decimals="0">7315</us-gaap:NetCashProvidedByUsedInInvestingActivities>

  <us-gaap:ProceedsFromWarrantExercises contextRef="P01_01_2013To06_30_2013" id="Factid_262" unitRef="USD" decimals="0">1723736</us-gaap:ProceedsFromWarrantExercises>

  <us-gaap:ProceedsFromWarrantExercises contextRef="P01_01_2012To06_30_2012" id="Factid_263" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromWarrantExercises>

  <us-gaap:ProceedsFromWarrantExercises contextRef="P12_01_2011To06_30_2013" id="Factid_264" unitRef="USD" decimals="0">1723736</us-gaap:ProceedsFromWarrantExercises>

  <us-gaap:RepaymentsOfShortTermDebt contextRef="P01_01_2013To06_30_2013" id="Factid_265" unitRef="USD" decimals="0">0</us-gaap:RepaymentsOfShortTermDebt>

  <us-gaap:RepaymentsOfShortTermDebt contextRef="P01_01_2012To06_30_2012" id="Factid_266" unitRef="USD" decimals="0">200000</us-gaap:RepaymentsOfShortTermDebt>

  <us-gaap:RepaymentsOfShortTermDebt contextRef="P12_01_2011To06_30_2013" id="Factid_267" unitRef="USD" decimals="0">200001</us-gaap:RepaymentsOfShortTermDebt>

  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="P01_01_2013To06_30_2013" id="Factid_268" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromIssuanceOfCommonStock>

  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="P01_01_2012To06_30_2012" id="Factid_269" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromIssuanceOfCommonStock>

  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="P12_01_2011To06_30_2013" id="Factid_270" unitRef="USD" decimals="0">9824682</us-gaap:ProceedsFromIssuanceOfCommonStock>

  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="P01_01_2013To06_30_2013" id="Factid_271" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>

  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="P01_01_2012To06_30_2012" id="Factid_272" unitRef="USD" decimals="0">12257309</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>

  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="P12_01_2011To06_30_2013" id="Factid_273" unitRef="USD" decimals="0">12257309</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>

  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="P01_01_2013To06_30_2013" id="Factid_274" unitRef="USD" decimals="0">0</us-gaap:PaymentsOfStockIssuanceCosts>

  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="P01_01_2012To06_30_2012" id="Factid_275" unitRef="USD" decimals="0">75903</us-gaap:PaymentsOfStockIssuanceCosts>

  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="P12_01_2011To06_30_2013" id="Factid_276" unitRef="USD" decimals="0">75903</us-gaap:PaymentsOfStockIssuanceCosts>

  <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="P01_01_2013To06_30_2013" id="Factid_277" unitRef="USD" decimals="0">0</us-gaap:PaymentsForRepurchaseOfCommonStock>

  <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="P01_01_2012To06_30_2012" id="Factid_278" unitRef="USD" decimals="0">0</us-gaap:PaymentsForRepurchaseOfCommonStock>

  <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="P12_01_2011To06_30_2013" id="Factid_279" unitRef="USD" decimals="0">84538</us-gaap:PaymentsForRepurchaseOfCommonStock>

  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="P01_01_2013To06_30_2013" id="Factid_280" unitRef="USD" decimals="0">1723736</us-gaap:NetCashProvidedByUsedInFinancingActivities>

  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="P01_01_2012To06_30_2012" id="Factid_281" unitRef="USD" decimals="0">11981406</us-gaap:NetCashProvidedByUsedInFinancingActivities>

  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="P12_01_2011To06_30_2013" id="Factid_282" unitRef="USD" decimals="0">23445285</us-gaap:NetCashProvidedByUsedInFinancingActivities>

  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="P01_01_2013To06_30_2013" id="Factid_283" unitRef="USD" decimals="0">-3039043</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>

  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="P01_01_2012To06_30_2012" id="Factid_284" unitRef="USD" decimals="0">10618588</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>

  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="P12_01_2011To06_30_2013" id="Factid_285" unitRef="USD" decimals="0">13416952</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2011" id="Factid_286" unitRef="USD" decimals="0">9748491</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn11_30_2011" id="Factid_287" unitRef="USD" decimals="0">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn06_30_2012" id="Factid_288" unitRef="USD" decimals="0">20367079</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <tgtx:ConversionOfNotesPayableToPreferredStock contextRef="P01_01_2013To06_30_2013" id="Factid_289" unitRef="USD" decimals="0">0</tgtx:ConversionOfNotesPayableToPreferredStock>

  <tgtx:ConversionOfNotesPayableToPreferredStock contextRef="P01_01_2012To06_30_2012" id="Factid_290" unitRef="USD" decimals="0">0</tgtx:ConversionOfNotesPayableToPreferredStock>

  <tgtx:ConversionOfNotesPayableToPreferredStock contextRef="P12_01_2011To06_30_2013" id="Factid_291" unitRef="USD" decimals="0">55271</tgtx:ConversionOfNotesPayableToPreferredStock>

  <tgtx:AccruedFinancingCosts contextRef="P01_01_2013To06_30_2013" id="Factid_292" unitRef="USD" decimals="0">0</tgtx:AccruedFinancingCosts>

  <tgtx:AccruedFinancingCosts contextRef="P01_01_2012To06_30_2012" id="Factid_293" unitRef="USD" decimals="0">0</tgtx:AccruedFinancingCosts>

  <tgtx:AccruedFinancingCosts contextRef="P12_01_2011To06_30_2013" id="Factid_294" unitRef="USD" decimals="0">61138</tgtx:AccruedFinancingCosts>

  <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="P01_01_2013To06_30_2013" id="Factid_295" unitRef="USD" decimals="0">90058</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>

  <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="P01_01_2012To06_30_2012" id="Factid_296" unitRef="USD" decimals="0">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>

  <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="P12_01_2011To06_30_2013" id="Factid_297" unitRef="USD" decimals="0">90058</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>

  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="P01_01_2013To06_30_2013" id="Factid_298">              &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;b&gt;NOTE 1 &amp;#150; ORGANIZATION AND SUMMARY OF  SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;b&gt;&lt;i&gt;Description of Business&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;We are a biopharmaceutical company focused on the  acquisition, development and commercialization of innovative and  medically important pharmaceutical products for the treatment of  cancer and other underserved therapeutic needs. We aim to acquire  rights to these technologies by licensing or otherwise acquiring an  ownership interest, funding their research and development and  eventually either out-licensing or bringing the technologies to  market. Currently, the Company is developing therapies for  hematologic malignancies: TG-1101 (ublituximab), a novel, third  generation monoclonal antibody that targets a specific and unique  epitope on the CD20 antigen found on mature B-lymphocytes; and  TGR-1202, an orally available PI3K delta inhibitor. We also hold  the development rights to AST-726, a nasally delivered product for  the treatment of Vitamin B12 deficiency.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;The accompanying unaudited condensed consolidated  financial statements were prepared in accordance with U.S.  generally accepted accounting principles (&amp;#8220;GAAP&amp;#8221;) for  interim financial information and with the instructions to Form  10-Q and Article&amp;#160;10 of Regulation&amp;#160;S-X. Accordingly, they  may not include all of the information and footnotes required by  GAAP for complete financial statements. All adjustments that are,  in the opinion of management, of a normal recurring nature and are  necessary for a fair presentation of the consolidated financial  statements have been included. Nevertheless, these consolidated  financial statements should be read in conjunction with the audited  consolidated financial statements contained in our Annual Report on  Form 10-K for the year ended December 31, 2012. The results of  operations for the three and six months ended June 30, 2013 are not  necessarily indicative of the results that may be expected for the  entire fiscal year or any other interim period.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;On December 29, 2011, the Company entered into and  consummated an exchange transaction agreement (the &amp;#8220;Exchange  Transaction&amp;#8221;) with Opus Point Partners, LLC  (&amp;#8220;Opus&amp;#8221;) and TG Biologics, Inc. (formerly known as TG  Therapeutics, Inc.) (&amp;#8220;TG Bio&amp;#8221;). The stockholders of TG  Bio received the majority of the voting shares of the Company,  therefore, the merger was accounted for as a reverse acquisition  whereby TG Bio was the accounting acquirer (legal acquiree) and the  Company was the accounting acquiree (legal acquirer) under the  acquisition method of accounting. TG Bio was incorporated in  Delaware in November 2010, but did not commence operations until  April 2011.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;On April 30, 2012, the Company filed a Certificate of  Amendment to its Certificate of Incorporation to change its name  from Manhattan Pharmaceuticals, Inc. (&amp;#8220;Manhattan&amp;#8221;) to  TG Therapeutics, Inc. In conjunction with this change, the  subsidiary formerly named TG Therapeutics, Inc. filed a Certificate  of Amendment changing its name to TG Biologics,  Inc.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;b&gt;&lt;i&gt;Liquidity and Capital Resources&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;We have incurred operating losses since our inception  and expect to continue to incur operating losses for the  foreseeable future, and we may never become profitable. As of June  30, 2013, we have an accumulated deficit of $&lt;font style=" FONT-SIZE: 10pt"&gt;29,183,956&lt;/font&gt;.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;Our major sources of cash have been proceeds from the  private placement of equity securities, the upfront payment from  our Sublicense Agreement with Ildong Pharmaceutical Co. Ltd.  (&amp;#8220;Ildong&amp;#8221;), and warrant exercises. We have not yet  commercialized any of our drug candidates and cannot be sure if we  will ever be able to do so. Even if we commercialize one or more of  our drug candidates, we may not become profitable. Our ability to  achieve profitability depends on a number of factors, including our  ability to obtain regulatory approval for our drug candidates,  successfully complete any post-approval regulatory obligations and  successfully commercialize our drug candidates alone or in  partnership. We may continue to incur substantial operating losses  even if we begin to generate revenues from our drug  candidates.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;font style="BACKGROUND-COLOR: transparent"&gt;On July  18, 2013, we announced the pricing of an underwritten public  offering of &lt;font style=" FONT-SIZE: 10pt"&gt;5,700,000&lt;/font&gt; shares  of our common stock at a price of $&lt;font style=" FONT-SIZE: 10pt"&gt;6.15&lt;/font&gt; per share for gross proceeds of  approximately $&lt;font style=" FONT-SIZE: 10pt"&gt;35&lt;/font&gt; million. We  also granted to the underwriters a 30-day option to acquire an  additional &lt;font style=" FONT-SIZE: 10pt"&gt;855,000&lt;/font&gt; shares to  cover overallotments in connection with the offering, which was  exercised on July 25, 2013. Total net proceeds from this offering,  including the overallotment, were approximately $&lt;font style=" FONT-SIZE: 10pt"&gt;37.4&lt;/font&gt; million, net of underwriting  discounts and estimated offering expenses of approximately $&lt;font  style=" FONT-SIZE: 10pt"&gt;2.9&lt;/font&gt; million. The shares were sold  under a shelf registration statement on Form S-3 (File No.  333-189015) that was previously filed and declared effective by the  SEC on June 17, 2013. We currently have one shelf registration  statement on Form S-3, filed and declared effective by the SEC.  Subsequent to the July 2013 offering, this shelf registration  statement provides for the offering of up to approximately $&lt;font  style=" FONT-SIZE: 10pt"&gt;135&lt;/font&gt; million of common stock. We may  offer the securities under our shelf registration statements from  time to time in response to market conditions or other  circumstances if we believe such a plan of financing is in the best  interests of our stockholders. We believe that these shelf  registration statements provide us with the flexibility to raise  additional capital to finance our operations as  needed.&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;font style="BACKGROUND-COLOR: transparent"&gt;  &amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;We currently anticipate that our cash and cash  equivalents, and the proceeds from the July 2013 public offering  are sufficient to fund our anticipated operating cash requirements  for approximately 30-36 months. The actual amount of cash that we  will need to operate is subject to many factors, including, but not  limited to, the timing, design and conduct of clinical trials for  our drug candidates. We are dependent upon significant future  financing to provide the cash necessary to execute our current  operations, including the commercialization of any of our drug  candidates.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;Our Common Stock is quoted on the &lt;font style="COLOR: black"&gt;NASDAQ Capital Market&lt;/font&gt; and trades under the  symbol &amp;#8220;TGTX.&amp;#8221;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  We treat liquid investments with original maturities of less than  three months when purchased as cash and cash equivalents.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;We recognize license revenue in accordance with the  revenue recognition guidance of the FASB Accounting Standards  Codification, or Codification. We analyze each element of our  licensing agreement to determine the appropriate revenue  recognition. The terms of the license agreement may include  payments to us of non-refundable up-front license fees, milestone  payments if specified objectives are achieved, and/or royalties on  product sales. We recognize revenue from upfront payments over the  period of significant involvement under the related agreements  unless the fee is in exchange for products delivered or services  rendered that represent the culmination of a separate earnings  process and no further performance obligation exists under the  contract. We recognize milestone payments as revenue upon the  achievement of specified milestones only if (1) the milestone  payment is non-refundable, (2) substantive effort is involved in  achieving the milestone, (3) the amount of the milestone is  reasonable in relation to the effort expended or the risk  associated with achievement of the milestone, and (4) the milestone  is at risk for both parties. If any of these conditions are not  met, we defer the milestone payment and recognize it as revenue  over the estimated period of performance under the contract.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;b&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;Generally, research and development costs are  expensed as incurred. Nonrefundable advance payments for goods or  services that will be used or rendered for future research and  development activities are deferred and amortized over the period  that the goods are delivered or the related services are performed,  subject to an assessment of recoverability. We make estimates of  costs incurred in relation to external clinical research  organizations, or CROs, and clinical site costs. We analyze the  progress of clinical trials, including levels of patient  enrollment, invoices received and contracted costs when evaluating  the adequacy of the amount expensed and the related prepaid asset  and accrued liability. Significant judgments and estimates must be  made and used in determining the accrued balance and expense in any  accounting period. We review and accrue CRO expenses and clinical  trial study expenses based on work performed and rely upon  estimates of those costs applicable to the stage of completion of a  study. Accrued CRO costs are subject to revisions as such trials  progress to completion. Revisions are charged to expense in the  period in which the facts that give rise to the revision become  known. With respect to clinical site costs, the financial terms of  these agreements are subject to negotiation and vary from contract  to contract. Payments under these contracts may be uneven, and  depend on factors such as the achievement of certain events, the  successful recruitment of patients, the completion of portions of  the clinical trial or similar conditions. The objective of our  policy is to match the recording of expenses in our financial  statements to the actual services received and efforts expended. As  such, expense accruals related to clinical site costs are  recognized based on our estimate of the degree of completion of the  event or events specified in the specific clinical study or trial  contract.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;b&gt;&lt;i&gt;In-Process Research and  Development&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0pt 0px; FONT: italic 10pt Times New Roman, Times, Serif"&gt;  &lt;font style="FONT-STYLE: normal; FONT-WEIGHT: normal"&gt;All acquired  research and development projects are recorded at their fair value  as of the date of acquisition. The fair values are assessed as of  the balance sheet date to ascertain if there has been any  impairment of the recorded value. If there is an impairment, the  asset is written down to its current fair value by the recording of  an expense. Impairment is tested on an annual basis, and consists  of a comparison of the fair value of the in-process research and  development with its carrying amount.&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;Income taxes are accounted for under the asset and  liability method. Deferred tax assets and liabilities are  recognized for the future tax consequences attributable to  temporary differences between the financial statement carrying  amounts of existing assets and liabilities and their respective tax  bases, operating losses and tax credit carryforwards. Deferred tax  assets and liabilities are measured using enacted tax rates  expected to apply to taxable income in the years in which those  temporary differences are expected to be recovered or settled. The  effect on deferred tax assets and liabilities of a change in tax  rates is recognized in operations in the period that includes the  enactment date. If the likelihood of realizing the deferred tax  assets or liability is less than &amp;#8220;more likely than  not,&amp;#8221; a valuation allowance is then created.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;We, and our subsidiaries, file income tax returns in  the U.S. Federal jurisdiction and in various states. We have tax  net operating loss carryforwards that are subject to examination  for a number of years beyond the year in which they were generated  for tax purposes. Since a portion of these net operating loss  carryforwards may be utilized in the future, many of these net  operating loss carryforwards will remain subject to  examination.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;We recognize interest and penalties related to  uncertain income tax positions in income tax expense.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  We recognize all share-based payments to employees and to  non-employee directors as compensation for service on our board of  directors as compensation expense in the consolidated financial  statements based on the fair values of such payments. Stock-based  compensation expense recognized each period is based on the value  of the portion of share-based payment awards that is ultimately  expected to vest during the period. Forfeitures are estimated at  the time of grant and revised, if necessary, in subsequent periods  if actual forfeitures differ from those estimates.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  For share-based payments to consultants and other third-parties,  compensation expense is determined at the &amp;#8220;measurement  date.&amp;#8221; The expense is recognized over the vesting period of  the award. Until the measurement date is reached, the total amount  of compensation expense remains uncertain. We record compensation  expense based on the fair value of the award at the reporting date.  The awards to consultants and other third-parties are then  revalued, or the total compensation is recalculated based on the  then current fair value, at each subsequent reporting date.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;b&gt;&lt;i&gt;Basic and Diluted Net (Loss) Income Per Share  of Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;Basic net income (loss) per share of Common Stock is  calculated by dividing net income (loss) applicable to the Common  Stock by the weighted-average number of the Common Stock  outstanding for the period. Diluted net loss per share of Common  Stock is the same as basic net income (loss) per share of Common  Stock since potentially dilutive securities from stock options,  stock warrants and convertible preferred stock would have an  antidilutive effect either because the Company incurred a net loss  during the period presented or because such potentially dilutive  securities were out of the money and the Company realized net  income during the period presented. The amounts of potentially  dilutive securities excluded from the calculation were &lt;font style=" FONT-SIZE: 10pt"&gt;10,114,847&lt;/font&gt; and &lt;font style=" FONT-SIZE: 10pt"&gt;7,433,525&lt;/font&gt; at June 30, 2013 and 2012,  respectively. During the three and six months ended June 30, 2013  and 2012, the Company incurred a net loss; therefore, all of the  dilutive securities are excluded from the computation of diluted  earnings per share.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;b&gt;&lt;i&gt;Long-Lived Assets and Goodwill&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;Long-lived assets are reviewed for an impairment loss  when circumstances indicate that the carrying value of long-lived  tangible and intangible assets with finite lives may not be  recoverable. Management&amp;#8217;s policy in determining whether an  impairment indicator exists, a triggering event, comprises  measurable operating performance criteria as well as qualitative  measures. If an analysis is necessitated by the occurrence of a  triggering event, we make certain assumptions in determining the  impairment amount. If the carrying amount of an asset exceeds its  estimated future cash flows, an impairment charge is  recognized.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;Goodwill is reviewed for impairment annually, or when  events arise that could indicate that an impairment exists. We test  for goodwill impairment using a two-step process. The first step  compares the fair value of the reporting unit with the unit's  carrying value, including goodwill. When the carrying value of the  reporting unit is greater than fair value, the unit&amp;#8217;s  goodwill may be impaired, and the second step must be completed to  measure the amount of the goodwill impairment charge, if any. In  the second step, the implied fair value of the reporting  unit&amp;#8217;s goodwill is compared with the carrying amount of the  unit&amp;#8217;s goodwill. If the carrying amount is greater than the  implied fair value, the carrying value of the goodwill must be  written down to its implied fair value. We will continue to perform  impairment tests annually, at December 31, and whenever events or  changes in circumstances suggest that the carrying value of an  asset may not be recoverable.&lt;/div&gt;  &lt;/div&gt;        </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>

  <tgtx:BusinessDescriptionPolicyTextBlock contextRef="P01_01_2013To06_30_2013" id="Factid_299">              &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;b&gt;&lt;i&gt;Description of Business&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;We are a biopharmaceutical company focused on the  acquisition, development and commercialization of innovative and  medically important pharmaceutical products for the treatment of  cancer and other underserved therapeutic needs. We aim to acquire  rights to these technologies by licensing or otherwise acquiring an  ownership interest, funding their research and development and  eventually either out-licensing or bringing the technologies to  market. Currently, the Company is developing therapies for  hematologic malignancies: TG-1101 (ublituximab), a novel, third  generation monoclonal antibody that targets a specific and unique  epitope on the CD20 antigen found on mature B-lymphocytes; and  TGR-1202, an orally available PI3K delta inhibitor. We also hold  the development rights to AST-726, a nasally delivered product for  the treatment of Vitamin B12 deficiency.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;The accompanying unaudited condensed consolidated  financial statements were prepared in accordance with U.S.  generally accepted accounting principles (&amp;#8220;GAAP&amp;#8221;) for  interim financial information and with the instructions to Form  10-Q and Article&amp;#160;10 of Regulation&amp;#160;S-X. Accordingly, they  may not include all of the information and footnotes required by  GAAP for complete financial statements. All adjustments that are,  in the opinion of management, of a normal recurring nature and are  necessary for a fair presentation of the consolidated financial  statements have been included. Nevertheless, these consolidated  financial statements should be read in conjunction with the audited  consolidated financial statements contained in our Annual Report on  Form 10-K for the year ended December 31, 2012. The results of  operations for the three and six months ended June 30, 2013 are not  necessarily indicative of the results that may be expected for the  entire fiscal year or any other interim period.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;On December 29, 2011, the Company entered into and  consummated an exchange transaction agreement (the &amp;#8220;Exchange  Transaction&amp;#8221;) with Opus Point Partners, LLC  (&amp;#8220;Opus&amp;#8221;) and TG Biologics, Inc. (formerly known as TG  Therapeutics, Inc.) (&amp;#8220;TG Bio&amp;#8221;). The stockholders of TG  Bio received the majority of the voting shares of the Company,  therefore, the merger was accounted for as a reverse acquisition  whereby TG Bio was the accounting acquirer (legal acquiree) and the  Company was the accounting acquiree (legal acquirer) under the  acquisition method of accounting. TG Bio was incorporated in  Delaware in November 2010, but did not commence operations until  April 2011.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;On April 30, 2012, the Company filed a Certificate of  Amendment to its Certificate of Incorporation to change its name  from Manhattan Pharmaceuticals, Inc. (&amp;#8220;Manhattan&amp;#8221;) to  TG Therapeutics, Inc. In conjunction with this change, the  subsidiary formerly named TG Therapeutics, Inc. filed a Certificate  of Amendment changing its name to TG Biologics,  Inc.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/div&gt;  &lt;/div&gt;        </tgtx:BusinessDescriptionPolicyTextBlock>

  <us-gaap:LiquidityDisclosureTextBlock contextRef="P01_01_2013To06_30_2013" id="Factid_300">              &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;b&gt;&lt;i&gt;Liquidity and Capital Resources&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;We have incurred operating losses since our inception  and expect to continue to incur operating losses for the  foreseeable future, and we may never become profitable. As of June  30, 2013, we have an accumulated deficit of $&lt;font style=" FONT-SIZE: 10pt"&gt;29,183,956&lt;/font&gt;.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;Our major sources of cash have been proceeds from the  private placement of equity securities, the upfront payment from  our Sublicense Agreement with Ildong Pharmaceutical Co. Ltd.  (&amp;#8220;Ildong&amp;#8221;), and warrant exercises. We have not yet  commercialized any of our drug candidates and cannot be sure if we  will ever be able to do so. Even if we commercialize one or more of  our drug candidates, we may not become profitable. Our ability to  achieve profitability depends on a number of factors, including our  ability to obtain regulatory approval for our drug candidates,  successfully complete any post-approval regulatory obligations and  successfully commercialize our drug candidates alone or in  partnership. We may continue to incur substantial operating losses  even if we begin to generate revenues from our drug  candidates.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;font style="BACKGROUND-COLOR: transparent"&gt;On July  18, 2013, we announced the pricing of an underwritten public  offering of &lt;font style=" FONT-SIZE: 10pt"&gt;5,700,000&lt;/font&gt; shares  of our common stock at a price of $&lt;font style=" FONT-SIZE: 10pt"&gt;6.15&lt;/font&gt; per share for gross proceeds of  approximately $&lt;font style=" FONT-SIZE: 10pt"&gt;35&lt;/font&gt; million. We  also granted to the underwriters a 30-day option to acquire an  additional &lt;font style=" FONT-SIZE: 10pt"&gt;855,000&lt;/font&gt; shares to  cover overallotments in connection with the offering, which was  exercised on July 25, 2013. Total net proceeds from this offering,  including the overallotment, were approximately $&lt;font style=" FONT-SIZE: 10pt"&gt;37.4&lt;/font&gt; million, net of underwriting  discounts and estimated offering expenses of approximately $&lt;font  style=" FONT-SIZE: 10pt"&gt;2.9&lt;/font&gt; million. The shares were sold  under a shelf registration statement on Form S-3 (File No.  333-189015) that was previously filed and declared effective by the  SEC on June 17, 2013. We currently have one shelf registration  statement on Form S-3, filed and declared effective by the SEC.  Subsequent to the July 2013 offering, this shelf registration  statement provides for the offering of up to approximately $&lt;font  style=" FONT-SIZE: 10pt"&gt;135&lt;/font&gt; million of common stock. We may  offer the securities under our shelf registration statements from  time to time in response to market conditions or other  circumstances if we believe such a plan of financing is in the best  interests of our stockholders. We believe that these shelf  registration statements provide us with the flexibility to raise  additional capital to finance our operations as  needed.&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;font style="BACKGROUND-COLOR: transparent"&gt;  &amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;We currently anticipate that our cash and cash  equivalents, and the proceeds from the July 2013 public offering  are sufficient to fund our anticipated operating cash requirements  for approximately 30-36 months. The actual amount of cash that we  will need to operate is subject to many factors, including, but not  limited to, the timing, design and conduct of clinical trials for  our drug candidates. We are dependent upon significant future  financing to provide the cash necessary to execute our current  operations, including the commercialization of any of our drug  candidates.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;Our Common Stock is quoted on the &lt;font style="COLOR: black"&gt;NASDAQ Capital Market&lt;/font&gt; and trades under the  symbol &amp;#8220;TGTX.&amp;#8221;&lt;/div&gt;  &lt;/div&gt;        </us-gaap:LiquidityDisclosureTextBlock>

  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2013To06_30_2013" id="Factid_301">              &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  We treat liquid investments with original maturities of less than  three months when purchased as cash and cash equivalents.&lt;/div&gt;  &lt;/div&gt;        </us-gaap:CashAndCashEquivalentsPolicyTextBlock>

  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="P01_01_2013To06_30_2013" id="Factid_302">              &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;We recognize license revenue in accordance with the  revenue recognition guidance of the FASB Accounting Standards  Codification, or Codification. We analyze each element of our  licensing agreement to determine the appropriate revenue  recognition. The terms of the license agreement may include  payments to us of non-refundable up-front license fees, milestone  payments if specified objectives are achieved, and/or royalties on  product sales. We recognize revenue from upfront payments over the  period of significant involvement under the related agreements  unless the fee is in exchange for products delivered or services  rendered that represent the culmination of a separate earnings  process and no further performance obligation exists under the  contract. We recognize milestone payments as revenue upon the  achievement of specified milestones only if (1) the milestone  payment is non-refundable, (2) substantive effort is involved in  achieving the milestone, (3) the amount of the milestone is  reasonable in relation to the effort expended or the risk  associated with achievement of the milestone, and (4) the milestone  is at risk for both parties. If any of these conditions are not  met, we defer the milestone payment and recognize it as revenue  over the estimated period of performance under the contract.&lt;/div&gt;  &lt;/div&gt;        </us-gaap:RevenueRecognitionPolicyTextBlock>

  <us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="P01_01_2013To06_30_2013" id="Factid_303">              &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;b&gt;&lt;i&gt;In-Process Research and  Development&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0pt 0px; FONT: italic 10pt Times New Roman, Times, Serif"&gt;  &lt;font style="FONT-STYLE: normal; FONT-WEIGHT: normal"&gt;All acquired  research and development projects are recorded at their fair value  as of the date of acquisition. The fair values are assessed as of  the balance sheet date to ascertain if there has been any  impairment of the recorded value. If there is an impairment, the  asset is written down to its current fair value by the recording of  an expense. Impairment is tested on an annual basis, and consists  of a comparison of the fair value of the in-process research and  development with its carrying amount.&lt;/font&gt;&lt;/div&gt;  &lt;/div&gt;        </us-gaap:InProcessResearchAndDevelopmentPolicy>

  <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2013To06_30_2013" id="Factid_304">              &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;Income taxes are accounted for under the asset and  liability method. Deferred tax assets and liabilities are  recognized for the future tax consequences attributable to  temporary differences between the financial statement carrying  amounts of existing assets and liabilities and their respective tax  bases, operating losses and tax credit carryforwards. Deferred tax  assets and liabilities are measured using enacted tax rates  expected to apply to taxable income in the years in which those  temporary differences are expected to be recovered or settled. The  effect on deferred tax assets and liabilities of a change in tax  rates is recognized in operations in the period that includes the  enactment date. If the likelihood of realizing the deferred tax  assets or liability is less than &amp;#8220;more likely than  not,&amp;#8221; a valuation allowance is then created.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;We, and our subsidiaries, file income tax returns in  the U.S. Federal jurisdiction and in various states. We have tax  net operating loss carryforwards that are subject to examination  for a number of years beyond the year in which they were generated  for tax purposes. Since a portion of these net operating loss  carryforwards may be utilized in the future, many of these net  operating loss carryforwards will remain subject to  examination.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;We recognize interest and penalties related to  uncertain income tax positions in income tax expense.&lt;/div&gt;  &lt;/div&gt;        </us-gaap:IncomeTaxPolicyTextBlock>

  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P01_01_2013To06_30_2013" id="Factid_305">              &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  We recognize all share-based payments to employees and to  non-employee directors as compensation for service on our board of  directors as compensation expense in the consolidated financial  statements based on the fair values of such payments. Stock-based  compensation expense recognized each period is based on the value  of the portion of share-based payment awards that is ultimately  expected to vest during the period. Forfeitures are estimated at  the time of grant and revised, if necessary, in subsequent periods  if actual forfeitures differ from those estimates.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  For share-based payments to consultants and other third-parties,  compensation expense is determined at the &amp;#8220;measurement  date.&amp;#8221; The expense is recognized over the vesting period of  the award. Until the measurement date is reached, the total amount  of compensation expense remains uncertain. We record compensation  expense based on the fair value of the award at the reporting date.  The awards to consultants and other third-parties are then  revalued, or the total compensation is recalculated based on the  then current fair value, at each subsequent reporting date.&lt;/div&gt;  &lt;/div&gt;        </us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>

  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2013To06_30_2013" id="Factid_306">              &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;b&gt;&lt;i&gt;Basic and Diluted Net (Loss) Income Per Share  of Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;Basic net income (loss) per share of Common Stock is  calculated by dividing net income (loss) applicable to the Common  Stock by the weighted-average number of the Common Stock  outstanding for the period. Diluted net loss per share of Common  Stock is the same as basic net income (loss) per share of Common  Stock since potentially dilutive securities from stock options,  stock warrants and convertible preferred stock would have an  antidilutive effect either because the Company incurred a net loss  during the period presented or because such potentially dilutive  securities were out of the money and the Company realized net  income during the period presented. The amounts of potentially  dilutive securities excluded from the calculation were &lt;font style=" FONT-SIZE: 10pt"&gt;10,114,847&lt;/font&gt; and &lt;font style=" FONT-SIZE: 10pt"&gt;7,433,525&lt;/font&gt; at June 30, 2013 and 2012,  respectively. During the three and six months ended June 30, 2013  and 2012, the Company incurred a net loss; therefore, all of the  dilutive securities are excluded from the computation of diluted  earnings per share.&lt;/div&gt;  &lt;/div&gt;        </us-gaap:EarningsPerSharePolicyTextBlock>

  <tgtx:ImpairmentOfTangibleAndIntangibleAssetIncludingGoodwillPolicyTextBlock contextRef="P01_01_2013To06_30_2013" id="Factid_307">              &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;b&gt;&lt;i&gt;Long-Lived Assets and Goodwill&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;Long-lived assets are reviewed for an impairment loss  when circumstances indicate that the carrying value of long-lived  tangible and intangible assets with finite lives may not be  recoverable. Management&amp;#8217;s policy in determining whether an  impairment indicator exists, a triggering event, comprises  measurable operating performance criteria as well as qualitative  measures. If an analysis is necessitated by the occurrence of a  triggering event, we make certain assumptions in determining the  impairment amount. If the carrying amount of an asset exceeds its  estimated future cash flows, an impairment charge is  recognized.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;Goodwill is reviewed for impairment annually, or when  events arise that could indicate that an impairment exists. We test  for goodwill impairment using a two-step process. The first step  compares the fair value of the reporting unit with the unit's  carrying value, including goodwill. When the carrying value of the  reporting unit is greater than fair value, the unit&amp;#8217;s  goodwill may be impaired, and the second step must be completed to  measure the amount of the goodwill impairment charge, if any. In  the second step, the implied fair value of the reporting  unit&amp;#8217;s goodwill is compared with the carrying amount of the  unit&amp;#8217;s goodwill. If the carrying amount is greater than the  implied fair value, the carrying value of the goodwill must be  written down to its implied fair value. We will continue to perform  impairment tests annually, at December 31, and whenever events or  changes in circumstances suggest that the carrying value of an  asset may not be recoverable.&lt;/div&gt;  &lt;/div&gt;        </tgtx:ImpairmentOfTangibleAndIntangibleAssetIncludingGoodwillPolicyTextBlock>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2013To06_30_2013" id="Factid_308" unitRef="shares" decimals="INF">10114847</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2012To06_30_2012" id="Factid_309" unitRef="shares" decimals="INF">7433525</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P07_01_2013To07_18_2013_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_310" unitRef="shares" decimals="INF">5700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="P07_01_2013To07_18_2013_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_311" unitRef="USD" decimals="-6">35000000</us-gaap:ProceedsFromIssuanceOfCommonStock>

  <tgtx:StockIssuedDuringPeriodSharesNewIssuesOverallotments contextRef="P07_01_2013To07_18_2013_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_312" unitRef="shares" decimals="INF">855000</tgtx:StockIssuedDuringPeriodSharesNewIssuesOverallotments>

  <tgtx:NetProceedsFromIssuanceOfCommonStock contextRef="P07_01_2013To07_18_2013_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_313" unitRef="USD" decimals="-5">37400000</tgtx:NetProceedsFromIssuanceOfCommonStock>

  <tgtx:UnderwritingDiscountsAndOfferingExpenses contextRef="P07_01_2013To07_18_2013_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_314" unitRef="USD" decimals="-5">2900000</tgtx:UnderwritingDiscountsAndOfferingExpenses>

  <tgtx:StockIssuedDuringPeriodSharesNewIssuesShelfRegistrationStatement contextRef="P07_01_2013To07_18_2013_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_315" unitRef="USD" decimals="-6">135000000</tgtx:StockIssuedDuringPeriodSharesNewIssuesShelfRegistrationStatement>

  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P01_01_2013To06_30_2013" id="Factid_316">              &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&lt;b&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;Generally, research and development costs are  expensed as incurred. Nonrefundable advance payments for goods or  services that will be used or rendered for future research and  development activities are deferred and amortized over the period  that the goods are delivered or the related services are performed,  subject to an assessment of recoverability. We make estimates of  costs incurred in relation to external clinical research  organizations, or CROs, and clinical site costs. We analyze the  progress of clinical trials, including levels of patient  enrollment, invoices received and contracted costs when evaluating  the adequacy of the amount expensed and the related prepaid asset  and accrued liability. Significant judgments and estimates must be  made and used in determining the accrued balance and expense in any  accounting period. We review and accrue CRO expenses and clinical  trial study expenses based on work performed and rely upon  estimates of those costs applicable to the stage of completion of a  study. Accrued CRO costs are subject to revisions as such trials  progress to completion. Revisions are charged to expense in the  period in which the facts that give rise to the revision become  known. With respect to clinical site costs, the financial terms of  these agreements are subject to negotiation and vary from contract  to contract. Payments under these contracts may be uneven, and  depend on factors such as the achievement of certain events, the  successful recruitment of patients, the completion of portions of  the clinical trial or similar conditions. The objective of our  policy is to match the recording of expenses in our financial  statements to the actual services received and efforts expended. As  such, expense accruals related to clinical site costs are  recognized based on our estimate of the degree of completion of the  event or events specified in the specific clinical study or trial  contract.&lt;/div&gt;  &lt;/div&gt;        </us-gaap:ResearchAndDevelopmentExpensePolicy>

  <us-gaap:SharePrice contextRef="PAsOn07_18_2013_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_317" unitRef="USD_per_Share" decimals="2">6.15</us-gaap:SharePrice>

  <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2013To06_30_2013" id="Factid_318">              &lt;table border="0" style="clear:both;width:100%; table-layout:fixed;"&gt;  &lt;tr&gt;  &lt;td&gt;&lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;NOTE 2 &amp;#150; FAIR VALUE MEASUREMENTS&lt;/strong&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  We measure certain financial assets and liabilities at fair value  on a recurring basis in the financial statements. The hierarchy  ranks the quality and reliability of inputs, or assumptions, used  in the determination of fair value and requires financial assets  and liabilities carried at fair value to be classified and  disclosed in one of the following three categories:&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"&gt;  &lt;table style="clear:both;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"   cellspacing="0" cellpadding="0" width="100%"&gt;  &lt;tr style="VERTICAL-ALIGN: top"&gt;  &lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;  &lt;td style="WIDTH: 0.25in"&gt;  &lt;div&gt;&lt;font style="FONT-FAMILY: Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left"&gt;  &lt;div&gt;Level 1 &amp;#150; quoted prices in active markets for identical  assets and liabilities;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"&gt;  &lt;table style="clear:both;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"   cellspacing="0" cellpadding="0" width="100%"&gt;  &lt;tr style="VERTICAL-ALIGN: top"&gt;  &lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;  &lt;td style="WIDTH: 0.25in"&gt;  &lt;div&gt;&lt;font style="FONT-FAMILY: Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left"&gt;  &lt;div&gt;Level 2 &amp;#150; inputs other than Level 1 quoted prices that  are directly or indirectly observable; and&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"&gt;  &lt;table style="clear:both;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"   cellspacing="0" cellpadding="0" width="100%"&gt;  &lt;tr style="VERTICAL-ALIGN: top"&gt;  &lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;  &lt;td style="WIDTH: 0.25in"&gt;  &lt;div&gt;&lt;font style="FONT-FAMILY: Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left"&gt;  &lt;div&gt;Level 3 &amp;#150; unobservable inputs that are not corroborated  by market data.&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  As of June 30, 2013 and December 31, 2012, the fair values of cash  and cash equivalents, and notes and interest payable approximate  their carrying value.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;font style="BACKGROUND-COLOR: transparent"&gt;Upon the merger between  Manhattan and Ariston Pharmaceuticals, Inc. (&amp;#8220;Ariston&amp;#8221;)  in March 2010, Ariston issued $&lt;font style=" FONT-SIZE: 10pt"&gt;15,452,793&lt;/font&gt; of five-year &lt;font style=" FONT-SIZE: 10pt"&gt;5&lt;/font&gt;% notes payable (the &amp;#8220;5%  Notes&amp;#8221;) in satisfaction of several note payable issuances.  The 5% Notes and accrued and unpaid interest thereon are  convertible at the option of the holder into Common Stock at the  conversion price of $&lt;font style=" FONT-SIZE: 10pt"&gt;1,125&lt;/font&gt;  per share. Ariston agreed to make quarterly payments on the 5%  Notes equal to &lt;font style=" FONT-SIZE: 10pt"&gt;50&lt;/font&gt;% of the net  product cash flow received from the exploitation or  commercialization of Ariston&amp;#8217;s product candidates, AST-726  and AST-915. The Company has no obligations under the 5% Notes  aside from a) 50% of the net product cash flows from  Ariston&amp;#8217;s product candidates, if any, payable to noteholders;  and b) the conversion feature, discussed above.&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  In connection with the Exchange Transaction in December 2011, the  Company performed a valuation of the assets and liabilities of  Manhattan immediately prior to the transaction. &lt;font style="BACKGROUND-COLOR: transparent; COLOR: black"&gt;The cumulative  liability including accrued and unpaid interest of these notes was  approximately $&lt;font style=" FONT-SIZE: 10pt"&gt;16,876,000&lt;/font&gt;  immediately prior to the Exchange Transaction, $&lt;font style=" FONT-SIZE: 10pt"&gt;17,727,000&lt;/font&gt; at December 31, 2012 and  $&lt;/font&gt;&lt;font style=" FONT-SIZE: 10pt"&gt;18,167,000&lt;/font&gt; &lt;font  style="BACKGROUND-COLOR: transparent; COLOR: black"&gt;at June 30,  2013.&lt;/font&gt; As these notes payable are tied directly to net  product cash flows derived from the preexisting products of the  Company, this note and accrued interest was recorded at fair value  of $&lt;font style=" FONT-SIZE: 10pt"&gt;3,287,700&lt;/font&gt; as of the date  of the Exchange Transaction. No payments have been made on these  notes as of June 30, 2013.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  We elected the fair value option for valuing the 5% Notes upon the  completion of the reverse merger with TG Bio, as discussed above.  The Company elected the fair value option in order to reflect in  our financial statements the assumptions that market participants  use in evaluating these financial instruments.&lt;/div&gt;    &amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;     &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  The valuation method used to estimate the 5% Notes&amp;#8217; fair  value is a discounted cash flow model, where the expected cash  flows of AST-726 are discounted to the present using a yield that  incorporates compensation for the probability of success in  clinical development and marketing, among other factors. The  discount rate used in this discounted cash flow model approximated  &lt;font style=" FONT-SIZE: 10pt"&gt;20&lt;/font&gt;% at December 31, 2012 and  June 30, 2013. The assumptions, assessments and projections of  future revenues are subject to uncertainties, are difficult to  predict and require significant judgment. The use of different  assumptions, applying different judgment to inherently subjective  matters and changes in future market conditions could result in  significantly different estimates of fair value and the differences  could be material to our consolidated financial statements.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  The following table provides the fair value measurements of  applicable financial liabilities as of December 31, 2012 and June  30, 2013:&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left;"&gt;  &lt;table style="clear:both;BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="47%" colspan="11"&gt;  &lt;div&gt;Financial&amp;#160;liabilities&amp;#160;at&amp;#160;fair&amp;#160;value&lt;br/&gt;   &amp;#160;as&amp;#160;of&amp;#160;December&amp;#160;31,&amp;#160;2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;1&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;2&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;3&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Total&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;5% Notes&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,479,098&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,479,098&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;Totals&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,479,098&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,479,098&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;  &lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left;"&gt;  &lt;table style="clear:both;BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="47%" colspan="11"&gt;  &lt;div&gt;Financial&amp;#160;liabilities&amp;#160;at&amp;#160;fair&amp;#160;value&lt;br/&gt;   &amp;#160;as&amp;#160;of&amp;#160;June&amp;#160;30,&amp;#160;2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;1&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;2&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;3&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Total&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;5% Notes&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,364,816&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,364,816&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;Totals&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,364,816&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,364,816&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;  &lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  The Level 3 amounts above represent the fair value of the 5% Notes  and related accrued interest.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  The following table summarizes the changes in Level 3 instruments  during the six months ended June 30, 2013:&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left;"&gt;  &lt;table style="clear:both;BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="57%"&gt;  &lt;div&gt;Fair value at December 31, 2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,479,098&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="57%"&gt;  &lt;div&gt;Interest accrued on face value of 5% Notes&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;439,168&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="57%"&gt;  &lt;div&gt;Change in fair value of Level 3 liabilities&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(553,450)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="57%"&gt;  &lt;div&gt;Fair value at June 30, 2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,364,816&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;  &lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  The change in the fair value of the Level 3 liabilities is reported  in other (income) expense in the accompanying condensed  consolidated statements of operations.&lt;/div&gt;  &lt;/div&gt;        </us-gaap:FairValueDisclosuresTextBlock>

  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="P01_01_2013To06_30_2013" id="Factid_319">              &lt;table border="0" style="clear:both;width:100%; table-layout:fixed;"&gt;  &lt;tr&gt;  &lt;td&gt;&lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  The following table provides the fair value measurements of  applicable financial liabilities as of December 31, 2012 and June  30, 2013:&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left;"&gt;  &lt;table style="clear:both;BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="47%" colspan="11"&gt;  &lt;div&gt;Financial&amp;#160;liabilities&amp;#160;at&amp;#160;fair&amp;#160;value&lt;br/&gt;   &amp;#160;as&amp;#160;of&amp;#160;December&amp;#160;31,&amp;#160;2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;1&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;2&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;3&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Total&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;5% Notes&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,479,098&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,479,098&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;Totals&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,479,098&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,479,098&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;  &lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left;"&gt;  &lt;table style="clear:both;BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="47%" colspan="11"&gt;  &lt;div&gt;Financial&amp;#160;liabilities&amp;#160;at&amp;#160;fair&amp;#160;value&lt;br/&gt;   &amp;#160;as&amp;#160;of&amp;#160;June&amp;#160;30,&amp;#160;2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;1&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;2&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;3&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Total&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;5% Notes&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,364,816&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,364,816&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;Totals&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,364,816&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,364,816&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;  &lt;/div&gt;  &lt;/div&gt;        </us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>

  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="P01_01_2013To06_30_2013" id="Factid_320">              &lt;table border="0" style="clear:both;width:100%; table-layout:fixed;"&gt;  &lt;tr&gt;  &lt;td&gt;&lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  The following table summarizes the changes in Level 3 instruments  during the six months ended June 30, 2013:&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left;"&gt;  &lt;table style="clear:both;BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="57%"&gt;  &lt;div&gt;Fair value at December 31, 2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,479,098&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="57%"&gt;  &lt;div&gt;Interest accrued on face value of 5% Notes&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;439,168&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="57%"&gt;  &lt;div&gt;Change in fair value of Level 3 liabilities&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(553,450)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="57%"&gt;  &lt;div&gt;Fair value at June 30, 2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,364,816&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;  &lt;/div&gt;  &lt;/div&gt;        </us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>

  <us-gaap:NotesIssued1 contextRef="P04_01_2009To03_31_2010_ManhattanAndAristonPharmaceuticalsMergerMembertgtxTypeOfTransactionAxis" id="Factid_321" unitRef="USD" decimals="0">15452793</us-gaap:NotesIssued1>

  <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="PAsOn03_31_2010_ManhattanAndAristonPharmaceuticalsMergerMembertgtxTypeOfTransactionAxis" id="Factid_322" unitRef="pure" decimals="2">0.05</us-gaap:DebtInstrumentInterestRateEffectivePercentage>

  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="PAsOn03_31_2010_ManhattanAndAristonPharmaceuticalsMergerMembertgtxTypeOfTransactionAxis" id="Factid_323" unitRef="USD_per_Share" decimals="0">1125</us-gaap:DebtInstrumentConvertibleConversionPrice1>

  <tgtx:PercentageOfCashProceedsFromOperationToRepayConvertibleDebt contextRef="P04_01_2009To03_31_2010_ManhattanAndAristonPharmaceuticalsMergerMembertgtxTypeOfTransactionAxis" id="Factid_324" unitRef="pure" decimals="1">0.5</tgtx:PercentageOfCashProceedsFromOperationToRepayConvertibleDebt>

  <us-gaap:DebtInstrumentCarryingAmount contextRef="PAsOn12_31_2011" id="Factid_325" unitRef="USD" decimals="0">16876000</us-gaap:DebtInstrumentCarryingAmount>

  <us-gaap:DebtInstrumentCarryingAmount contextRef="PAsOn12_31_2012" id="Factid_326" unitRef="USD" decimals="0">17727000</us-gaap:DebtInstrumentCarryingAmount>

  <us-gaap:DebtInstrumentCarryingAmount contextRef="PAsOn06_30_2013" id="Factid_327" unitRef="USD" decimals="0">18167000</us-gaap:DebtInstrumentCarryingAmount>

  <us-gaap:DebtInstrumentFairValue contextRef="PAsOn12_31_2011" id="Factid_328" unitRef="USD" decimals="0">3287700</us-gaap:DebtInstrumentFairValue>

  <us-gaap:FairValueInputsDiscountRate contextRef="P01_01_2012To12_31_2012" id="Factid_329" unitRef="pure" decimals="1">0.2</us-gaap:FairValueInputsDiscountRate>

  <us-gaap:FairValueInputsDiscountRate contextRef="P01_01_2013To06_30_2013" id="Factid_330" unitRef="pure" decimals="1">0.2</us-gaap:FairValueInputsDiscountRate>

  <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="PAsOn06_30_2013_ManhattanAndAristonPharmaceuticalsMergerMembertgtxTypeOfTransactionAxis" id="Factid_331" unitRef="pure" decimals="2">0.05</us-gaap:DebtInstrumentInterestRateEffectivePercentage>

  <tgtx:DebtInstrumentMaturityPeriod contextRef="P04_01_2009To03_31_2010_ManhattanAndAristonPharmaceuticalsMergerMembertgtxTypeOfTransactionAxis" id="Factid_332">P5Y</tgtx:DebtInstrumentMaturityPeriod>

  <us-gaap:LiabilitiesFairValueDisclosure contextRef="PAsOn12_31_2012" id="Factid_333" unitRef="USD" decimals="0">2479098</us-gaap:LiabilitiesFairValueDisclosure>

  <us-gaap:LiabilitiesFairValueDisclosure contextRef="PAsOn12_31_2012_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_334" unitRef="USD" decimals="0">0</us-gaap:LiabilitiesFairValueDisclosure>

  <us-gaap:LiabilitiesFairValueDisclosure contextRef="PAsOn12_31_2012_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_335" unitRef="USD" decimals="0">0</us-gaap:LiabilitiesFairValueDisclosure>

  <us-gaap:LiabilitiesFairValueDisclosure contextRef="PAsOn12_31_2012_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_336" unitRef="USD" decimals="0">2479098</us-gaap:LiabilitiesFairValueDisclosure>

  <us-gaap:NotesPayableFairValueDisclosure contextRef="PAsOn12_31_2012" id="Factid_337" unitRef="USD" decimals="0">2479098</us-gaap:NotesPayableFairValueDisclosure>

  <us-gaap:NotesPayableFairValueDisclosure contextRef="PAsOn12_31_2012_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_338" unitRef="USD" decimals="0">0</us-gaap:NotesPayableFairValueDisclosure>

  <us-gaap:NotesPayableFairValueDisclosure contextRef="PAsOn12_31_2012_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_339" unitRef="USD" decimals="0">0</us-gaap:NotesPayableFairValueDisclosure>

  <us-gaap:NotesPayableFairValueDisclosure contextRef="PAsOn12_31_2012_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_340" unitRef="USD" decimals="0">2479098</us-gaap:NotesPayableFairValueDisclosure>

  <us-gaap:LiabilitiesFairValueDisclosure contextRef="PAsOn06_30_2013" id="Factid_341" unitRef="USD" decimals="0">2364816</us-gaap:LiabilitiesFairValueDisclosure>

  <us-gaap:LiabilitiesFairValueDisclosure contextRef="PAsOn06_30_2013_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_342" unitRef="USD" decimals="0">0</us-gaap:LiabilitiesFairValueDisclosure>

  <us-gaap:LiabilitiesFairValueDisclosure contextRef="PAsOn06_30_2013_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_343" unitRef="USD" decimals="0">0</us-gaap:LiabilitiesFairValueDisclosure>

  <us-gaap:LiabilitiesFairValueDisclosure contextRef="PAsOn06_30_2013_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_344" unitRef="USD" decimals="0">2364816</us-gaap:LiabilitiesFairValueDisclosure>

  <us-gaap:NotesPayableFairValueDisclosure contextRef="PAsOn06_30_2013" id="Factid_345" unitRef="USD" decimals="0">2364816</us-gaap:NotesPayableFairValueDisclosure>

  <us-gaap:NotesPayableFairValueDisclosure contextRef="PAsOn06_30_2013_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_346" unitRef="USD" decimals="0">0</us-gaap:NotesPayableFairValueDisclosure>

  <us-gaap:NotesPayableFairValueDisclosure contextRef="PAsOn06_30_2013_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_347" unitRef="USD" decimals="0">0</us-gaap:NotesPayableFairValueDisclosure>

  <us-gaap:NotesPayableFairValueDisclosure contextRef="PAsOn06_30_2013_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_348" unitRef="USD" decimals="0">2364816</us-gaap:NotesPayableFairValueDisclosure>

  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="PAsOn12_31_2012" id="Factid_349" unitRef="USD" decimals="0">2479098</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>

  <tgtx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings contextRef="P01_01_2013To06_30_2013" id="Factid_350" unitRef="USD" decimals="0">439168</tgtx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings>

  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease contextRef="P01_01_2013To06_30_2013" id="Factid_351" unitRef="USD" decimals="0">-553450</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>

  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="PAsOn06_30_2013" id="Factid_352" unitRef="USD" decimals="0">2364816</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>

  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2013To06_30_2013" id="Factid_353">              &lt;table border="0" style="clear:both;width:100%; table-layout:fixed;"&gt;  &lt;tr&gt;  &lt;td&gt;&lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  The following table summarizes stock option activity for the six  months ended June 30, 2013:&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="clear:both;BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Number&amp;#160;&lt;br/&gt;   &amp;#160;of&amp;#160;shares&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Weighted-&lt;br/&gt;   &amp;#160;&amp;#160;average&lt;br/&gt;   &amp;#160;&amp;#160;exercise&lt;br/&gt;   price&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Weighted-&lt;br/&gt;   &amp;#160;&amp;#160;average&lt;br/&gt;   &amp;#160;&amp;#160;Contractual&lt;br/&gt;   Term&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Aggregate&lt;br/&gt;   Intrinsic&lt;br/&gt;   Value&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;(in&amp;#160;years)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;Outstanding at December 31, 2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;46,904&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;61.08&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;9.44&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;Granted&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;Exercised&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;Forfeited&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(313)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,249.85&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;Expired&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;Outstanding at June 30, 2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;46,591&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;46.37&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;9.01&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;91,540&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;Vested and expected to vest at June 30, 2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;9,591&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;208.30&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;8.66&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;17,910&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;Exercisable at June 30, 2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;9,591&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;208.30&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;8.66&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;17,910&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt;  &lt;/div&gt;  &lt;/div&gt;  &lt;/div&gt;        </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>

  <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="P01_01_2013To06_30_2013" id="Factid_354">              &lt;table border="0" style="clear:both;width:100%; table-layout:fixed;"&gt;  &lt;tr&gt;  &lt;td&gt;&lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  The following table summarizes restricted share activity for the  six months ended June 30, 2013:&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="clear:both;BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="50%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Number&amp;#160;of&lt;br/&gt;   Shares&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Weighted&lt;br/&gt;   Average&amp;#160;Grant&lt;br/&gt;   Date&amp;#160;Fair&lt;br/&gt;   Value&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="50%"&gt;  &lt;div&gt;Outstanding at December 31, 2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;6,614,243&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;4.49&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="50%"&gt;  &lt;div&gt;Granted&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;147,044&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;6.04&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="50%"&gt;  &lt;div&gt;Vested&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(298,125)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2.39&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="50%"&gt;  &lt;div&gt;Forfeited&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="50%"&gt;  &lt;div&gt;Outstanding at June 30, 2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;6,463,162&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;4.63&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt;  &lt;/div&gt;  &lt;/div&gt;        </us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>

  <tgtx:ScheduleOfWarrantsActivityTableTextBlock contextRef="P01_01_2013To06_30_2013" id="Factid_355">              &lt;table border="0" style="clear:both;width:100%; table-layout:fixed;"&gt;  &lt;tr&gt;  &lt;td&gt;&lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  The following table summarizes warrant activity for the six months  ended June 30, 2013:&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="clear:both;BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="33%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Warrants&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Weighted-&lt;br/&gt;   &amp;#160;&amp;#160;average&lt;br/&gt;   &amp;#160;&amp;#160;exercise&amp;#160;price&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Aggregate&lt;br/&gt;   Intrinsic&lt;br/&gt;   Value&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="33%"&gt;  &lt;div&gt;Outstanding at December 31, 2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;6,781,007&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;1.58&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;14,563,539&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="33%"&gt;  &lt;div&gt;Issued&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="33%"&gt;  &lt;div&gt;Exercised&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;768,543&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2.25&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="33%"&gt;  &lt;div&gt;Expired&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="33%"&gt;  &lt;div&gt;Outstanding at June 30, 2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;6,012,464&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;1.49&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;30,251,181&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;  &lt;/div&gt;  &lt;/div&gt;        </tgtx:ScheduleOfWarrantsActivityTableTextBlock>

  <tgtx:ScheduleOfShareBasedCompensationExpenseTableTextBlock contextRef="P01_01_2013To06_30_2013" id="Factid_356">              &lt;table border="0" style="clear:both;width:100%; table-layout:fixed;"&gt;  &lt;tr&gt;  &lt;td&gt;&lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  The following table summarizes stock-based compensation expense  information about stock options and restricted stock for the three  and six months ended June 30, 2013:&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="clear:both;BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="71%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="13%" colspan="2"&gt;  &lt;div&gt;Three&amp;#160;months&lt;br/&gt;   ended&lt;br/&gt;   June&amp;#160;30, 2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="13%" colspan="2"&gt;  &lt;div&gt;Six&amp;#160;months&lt;br/&gt;   ended&lt;br/&gt;   June&amp;#160;30, 2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="71%"&gt;  &lt;div&gt;Stock-based compensation expense associated with restricted  stock&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="12%"&gt;  &lt;div&gt;1,317,363&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="12%"&gt;  &lt;div&gt;3,202,840&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="71%"&gt;  &lt;div&gt;Stock-based compensation expense associated with option  grants&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="12%"&gt;  &lt;div&gt;56,405&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="12%"&gt;  &lt;div&gt;56,405&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="71%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="12%"&gt;  &lt;div&gt;1,373,768&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="12%"&gt;  &lt;div&gt;3,259,245&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt;  &lt;/div&gt;  &lt;/div&gt;  &lt;/div&gt;        </tgtx:ScheduleOfShareBasedCompensationExpenseTableTextBlock>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="PAsOn06_30_2013_EquityIncentivePlansMemberusgaapPlanNameAxis" id="Factid_357" unitRef="shares" decimals="INF">1905213</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>

  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="PAsOn06_30_2013" id="Factid_358" unitRef="USD" decimals="0">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>

  <tgtx:ShareBasedCompensationNonEmployeeStockOptionsOutstanding contextRef="PAsOn06_30_2013" id="Factid_359" unitRef="shares" decimals="INF">37000</tgtx:ShareBasedCompensationNonEmployeeStockOptionsOutstanding>

  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="PAsOn06_30_2013_RestrictedStockMemberusgaapPlanNameAxis" id="Factid_360" unitRef="USD" decimals="0">8125000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>

  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2013To06_30_2013_RestrictedStockMemberusgaapPlanNameAxis" id="Factid_361">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>

  <tgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingNumber contextRef="PAsOn06_30_2013_CorporateMilestoneMembertgtxCorporateMilestoneAxis" id="Factid_362" unitRef="shares" decimals="INF">1517500</tgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingNumber>

  <tgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingNumber contextRef="PAsOn06_30_2013_NonEmployeeRestrictedStockMembertgtxNonEmployeeStockOptionsAxis" id="Factid_363" unitRef="shares" decimals="INF">2580000</tgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingNumber>

  <tgtx:StockIssuedDuringPeriodSharesNewIssuesShelfRegistrationStatement contextRef="P01_01_2013To06_30_2013_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_364" unitRef="USD" decimals="-6">135000000</tgtx:StockIssuedDuringPeriodSharesNewIssuesShelfRegistrationStatement>

  <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="P01_01_2013To06_30_2013" id="Factid_365">              &lt;table border="0" style="clear:both;width:100%; table-layout:fixed;"&gt;  &lt;tr&gt;  &lt;td&gt;&lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;NOTE 3 - STOCKHOLDERS' EQUITY&lt;/strong&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;&lt;em&gt;Preferred Stock&lt;/em&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  Our amended and restated certificate of incorporation authorizes  the issuance of up to &lt;font style=" FONT-SIZE: 10pt"&gt;  10,000,000&lt;/font&gt; shares of preferred stock, $&lt;font style=" FONT-SIZE: 10pt"&gt;0.001&lt;/font&gt; par value, with rights senior to  those of our common stock, &lt;font style="BACKGROUND-COLOR: transparent; COLOR: black"&gt;issuable in one or  more series. Upon issuance, the Company can determine the rights,  preferences, privileges and restrictions thereof. These rights,  preferences and privileges could include dividend rights,  conversion rights, voting rights, terms of redemption, liquidation  preferences, sinking fund terms and the number of shares  constituting any series or the designation of such series, any or  all of which may be greater than the rights of common  stock.&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;&lt;em&gt;Common Stock&lt;/em&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  Our amended and restated certificate of incorporation authorizes  the issuance of up to &lt;font style=" FONT-SIZE: 10pt"&gt;  500,000,000&lt;/font&gt; shares of $&lt;font style=" FONT-SIZE: 10pt"&gt;0.001&lt;/font&gt; par value common stock.&lt;/div&gt;    &amp;#160;&amp;#160;&amp;#160;&amp;#160;     &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;font style="BACKGROUND-COLOR: transparent"&gt;We currently have one  shelf registration statement on Form S-3, filed and declared  effective by the SEC (File No. 333-189015). Subsequent to the July  2013 offering, this shelf registration statement provides for the  offering of up to approximately $&lt;font style=" FONT-SIZE: 10pt"&gt;135&lt;/font&gt; million of common stock. See Note 7  &amp;#150; Subsequent Events. We may offer the securities under our  shelf registration statements from time to time in response to  market conditions or other circumstances if we believe such a plan  of financing is in the best interests of our stockholders. We  believe that these shelf registration statements provide us with  the flexibility to raise additional capital to finance our  operations as needed.&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;&lt;em&gt;Equity Incentive Plans&lt;/em&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  Shares available for the issuance of stock options or other  stock-based awards under our stock option and incentive plans were  &lt;font style=" FONT-SIZE: 10pt"&gt;1,905,213&lt;/font&gt; shares at June 30,  2013.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;u&gt;Stock Options&lt;/u&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  The following table summarizes stock option activity for the six  months ended June 30, 2013:&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="clear:both;BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Number&amp;#160;&lt;br/&gt;   &amp;#160;of&amp;#160;shares&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Weighted-&lt;br/&gt;   &amp;#160;&amp;#160;average&lt;br/&gt;   &amp;#160;&amp;#160;exercise&lt;br/&gt;   price&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Weighted-&lt;br/&gt;   &amp;#160;&amp;#160;average&lt;br/&gt;   &amp;#160;&amp;#160;Contractual&lt;br/&gt;   Term&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Aggregate&lt;br/&gt;   Intrinsic&lt;br/&gt;   Value&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;(in&amp;#160;years)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;Outstanding at December 31, 2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;46,904&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;61.08&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;9.44&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;Granted&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;Exercised&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;Forfeited&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(313)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,249.85&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;Expired&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;Outstanding at June 30, 2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;46,591&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;46.37&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;9.01&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;91,540&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;Vested and expected to vest at June 30, 2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;9,591&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;208.30&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;8.66&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;17,910&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;Exercisable at June 30, 2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;9,591&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;208.30&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;8.66&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;17,910&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt;  &lt;/div&gt;  &lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  As of June 30, 2013, the total compensation cost related to  unvested time-based option awards not yet recognized was $&lt;font  style=" FONT-SIZE: 10pt"&gt;0&lt;/font&gt;. This amount does not include, as  of June 30, 2013, &lt;font style=" FONT-SIZE: 10pt"&gt;37,000&lt;/font&gt;  non-employee options outstanding which are milestone-based and vest  upon certain corporate milestones. Stock-based compensation will be  measured and recorded if and when a milestone occurs.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;u&gt;Restricted Stock&lt;/u&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;font style="COLOR: black"&gt;Certain employees, directors and  consultants have been awarded restricted stock under the 2012  Incentive Plan.&lt;/font&gt; The restricted stock vesting consists of  milestone and time-based vesting. The following table summarizes  restricted share activity for the six months ended June 30,  2013:&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="clear:both;BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="50%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Number&amp;#160;of&lt;br/&gt;   Shares&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Weighted&lt;br/&gt;   Average&amp;#160;Grant&lt;br/&gt;   Date&amp;#160;Fair&lt;br/&gt;   Value&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="50%"&gt;  &lt;div&gt;Outstanding at December 31, 2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;6,614,243&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;4.49&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="50%"&gt;  &lt;div&gt;Granted&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;147,044&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;6.04&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="50%"&gt;  &lt;div&gt;Vested&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(298,125)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2.39&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="50%"&gt;  &lt;div&gt;Forfeited&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="50%"&gt;  &lt;div&gt;Outstanding at June 30, 2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;6,463,162&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;4.63&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt;  &lt;/div&gt;  &lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: -1pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  Total expense associated with restricted stock grants was  $3,202,840 during the six months ended June 30, 2013. As of June  30, 2013, there was approximately $&lt;font style=" FONT-SIZE: 10pt"&gt;8,125,000&lt;/font&gt; of total unrecognized  compensation cost related to unvested time based restricted stock,  which is expected to be recognized over a weighted-average period  of &lt;font style=" FONT-SIZE: 10pt"&gt;2.3&lt;/font&gt; years. This amount  does not include, as of June 30, 2013, &lt;font style=" FONT-SIZE: 10pt"&gt;1,517,500&lt;/font&gt; shares of restricted stock  outstanding which are milestone-based and vest upon certain  corporate milestones; and &lt;font style=" FONT-SIZE: 10pt"&gt;  2,580,000&lt;/font&gt; shares of restricted stock outstanding issued to  non-employees. Milestone based noncash compensation expense will be  measured and recorded if and when a milestone occurs.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;u&gt;Warrants&lt;/u&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  The following table summarizes warrant activity for the six months  ended June 30, 2013:&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="clear:both;BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="33%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Warrants&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Weighted-&lt;br/&gt;   &amp;#160;&amp;#160;average&lt;br/&gt;   &amp;#160;&amp;#160;exercise&amp;#160;price&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Aggregate&lt;br/&gt;   Intrinsic&lt;br/&gt;   Value&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="33%"&gt;  &lt;div&gt;Outstanding at December 31, 2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;6,781,007&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;1.58&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;14,563,539&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="33%"&gt;  &lt;div&gt;Issued&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="33%"&gt;  &lt;div&gt;Exercised&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;768,543&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2.25&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="33%"&gt;  &lt;div&gt;Expired&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="33%"&gt;  &lt;div&gt;Outstanding at June 30, 2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;6,012,464&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;1.49&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;30,251,181&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;  &lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;&lt;em&gt;Stock-Based Compensation&lt;/em&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  The fair value of stock options granted is estimated at the date of  grant using the Black-Scholes pricing model. The expected term of  options granted is derived from historical data and the expected  vesting period. Expected volatility is based on the historical  volatility of our common stock. The risk-free interest rate is  based on the U.S. Treasury yield for a period consistent with the  expected term of the option in effect at the time of the grant. We  have assumed no expected dividend yield, as dividends have never  been paid to stock or option holders and will not be paid for the  foreseeable future. The Company did not grant any stock options  during the six months ended June 30, 2013.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  The following table summarizes stock-based compensation expense  information about stock options and restricted stock for the three  and six months ended June 30, 2013:&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="clear:both;BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="71%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="13%" colspan="2"&gt;  &lt;div&gt;Three&amp;#160;months&lt;br/&gt;   ended&lt;br/&gt;   June&amp;#160;30, 2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="13%" colspan="2"&gt;  &lt;div&gt;Six&amp;#160;months&lt;br/&gt;   ended&lt;br/&gt;   June&amp;#160;30, 2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="71%"&gt;  &lt;div&gt;Stock-based compensation expense associated with restricted  stock&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="12%"&gt;  &lt;div&gt;1,317,363&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="12%"&gt;  &lt;div&gt;3,202,840&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="71%"&gt;  &lt;div&gt;Stock-based compensation expense associated with option  grants&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="12%"&gt;  &lt;div&gt;56,405&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="12%"&gt;  &lt;div&gt;56,405&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="71%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="12%"&gt;  &lt;div&gt;1,373,768&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="12%"&gt;  &lt;div&gt;3,259,245&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;  &lt;/div&gt;  &lt;/div&gt;        </us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn12_31_2012" id="Factid_366" unitRef="shares" decimals="INF">46904</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="P01_01_2013To06_30_2013" id="Factid_367" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>

  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="P01_01_2013To06_30_2013" id="Factid_368" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="P01_01_2013To06_30_2013" id="Factid_369" unitRef="shares" decimals="INF">313</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="P01_01_2013To06_30_2013" id="Factid_370" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn06_30_2013" id="Factid_371" unitRef="shares" decimals="INF">46591</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="PAsOn06_30_2013" id="Factid_372" unitRef="shares" decimals="INF">9591</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn06_30_2013" id="Factid_373" unitRef="shares" decimals="INF">9591</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2012" id="Factid_374" unitRef="USD_per_Share" decimals="2">61.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="P01_01_2013To06_30_2013" id="Factid_375" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="P01_01_2013To06_30_2013" id="Factid_376" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="P01_01_2013To06_30_2013" id="Factid_377" unitRef="USD_per_Share" decimals="2">2249.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="P01_01_2013To06_30_2013" id="Factid_378" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn06_30_2013" id="Factid_379" unitRef="USD_per_Share" decimals="2">46.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="PAsOn06_30_2013" id="Factid_380" unitRef="USD_per_Share" decimals="2">208.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="PAsOn06_30_2013" id="Factid_381" unitRef="USD_per_Share" decimals="2">208.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>

  <tgtx:SharesBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm contextRef="P01_01_2013To06_30_2013" id="Factid_382">P9Y5M8D</tgtx:SharesBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2013To06_30_2013" id="Factid_383">P9Y4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2013To06_30_2013" id="Factid_384">P8Y7M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2013To06_30_2013" id="Factid_385">P8Y7M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="PAsOn12_31_2012" id="Factid_386" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="PAsOn06_30_2013" id="Factid_387" unitRef="USD" decimals="0">91540</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="PAsOn06_30_2013" id="Factid_388" unitRef="USD" decimals="0">17910</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="PAsOn06_30_2013" id="Factid_389" unitRef="USD" decimals="0">17910</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="PAsOn12_31_2012_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_390" unitRef="shares" decimals="INF">6614243</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="P01_01_2013To06_30_2013_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_391" unitRef="shares" decimals="INF">147044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="P01_01_2013To06_30_2013_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_392" unitRef="shares" decimals="INF">298125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="P01_01_2013To06_30_2013_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_393" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="PAsOn06_30_2013_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_394" unitRef="shares" decimals="INF">6463162</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="PAsOn12_31_2012_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_395" unitRef="USD_per_Share" decimals="2">4.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="P01_01_2013To06_30_2013_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_396" unitRef="USD_per_Share" decimals="2">6.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="P01_01_2013To06_30_2013_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_397" unitRef="USD_per_Share" decimals="2">2.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="P01_01_2013To06_30_2013_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_398" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="PAsOn06_30_2013_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_399" unitRef="USD_per_Share" decimals="2">4.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>

  <tgtx:WarrantOrRightOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2012" id="Factid_400" unitRef="USD_per_Share" decimals="2">1.58</tgtx:WarrantOrRightOutstandingWeightedAverageExercisePrice>

  <tgtx:WarrantOrRightIssuedWeightedAverageExercisePrice contextRef="P01_01_2013To06_30_2013" id="Factid_401" unitRef="USD_per_Share" decimals="0">0</tgtx:WarrantOrRightIssuedWeightedAverageExercisePrice>

  <tgtx:WarrantOrRightExercisedWeightedAverageExercisePrice contextRef="P01_01_2013To06_30_2013" id="Factid_402" unitRef="USD_per_Share" decimals="2">2.25</tgtx:WarrantOrRightExercisedWeightedAverageExercisePrice>

  <tgtx:WarrantOrRightExpiredWeightedAverageExercisePrice contextRef="P01_01_2013To06_30_2013" id="Factid_403" unitRef="USD_per_Share" decimals="0">0</tgtx:WarrantOrRightExpiredWeightedAverageExercisePrice>

  <tgtx:WarrantOrRightOutstandingWeightedAverageExercisePrice contextRef="PAsOn06_30_2013" id="Factid_404" unitRef="USD_per_Share" decimals="2">1.49</tgtx:WarrantOrRightOutstandingWeightedAverageExercisePrice>

  <tgtx:WarrantOrRightAggregateIntrinsicValue contextRef="PAsOn06_30_2013" id="Factid_405" unitRef="USD" decimals="0">30251181</tgtx:WarrantOrRightAggregateIntrinsicValue>

  <tgtx:WarrantOrRightAggregateIntrinsicValue contextRef="PAsOn12_31_2012" id="Factid_406" unitRef="USD" decimals="0">14563539</tgtx:WarrantOrRightAggregateIntrinsicValue>

  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="PAsOn12_31_2012" id="Factid_407" unitRef="shares" decimals="INF">6781007</us-gaap:ClassOfWarrantOrRightOutstanding>

  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="PAsOn06_30_2013" id="Factid_408" unitRef="shares" decimals="INF">6012464</us-gaap:ClassOfWarrantOrRightOutstanding>

  <tgtx:WarrantOrRightIssued contextRef="P01_01_2013To06_30_2013" id="Factid_409" unitRef="shares" decimals="INF">0</tgtx:WarrantOrRightIssued>

  <tgtx:WarrantOrRightExercised contextRef="P01_01_2013To06_30_2013" id="Factid_410" unitRef="shares" decimals="INF">-768543</tgtx:WarrantOrRightExercised>

  <tgtx:WarrantOrRightExpired contextRef="P01_01_2013To06_30_2013" id="Factid_411" unitRef="shares" decimals="INF">0</tgtx:WarrantOrRightExpired>

  <us-gaap:RestrictedStockExpense contextRef="P04_01_2013To06_30_2013" id="Factid_412" unitRef="USD" decimals="0">1317363</us-gaap:RestrictedStockExpense>

  <us-gaap:RestrictedStockExpense contextRef="P01_01_2013To06_30_2013" id="Factid_413" unitRef="USD" decimals="0">3202840</us-gaap:RestrictedStockExpense>

  <us-gaap:StockOptionPlanExpense contextRef="P04_01_2013To06_30_2013" id="Factid_414" unitRef="USD" decimals="0">56405</us-gaap:StockOptionPlanExpense>

  <us-gaap:StockOptionPlanExpense contextRef="P01_01_2013To06_30_2013" id="Factid_415" unitRef="USD" decimals="0">56405</us-gaap:StockOptionPlanExpense>

  <us-gaap:ShareBasedCompensation contextRef="P04_01_2013To06_30_2013" id="Factid_416" unitRef="USD" decimals="0">1373768</us-gaap:ShareBasedCompensation>

  <us-gaap:DebtDisclosureTextBlock contextRef="P01_01_2013To06_30_2013" id="Factid_417">              &lt;table border="0" style="clear:both;width:100%; table-layout:fixed;"&gt;  &lt;tr&gt;  &lt;td&gt;&lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;NOTE 4 &amp;#150; NOTES PAYABLE&lt;/strong&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  The following is a summary of notes payable:&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="clear:both;BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="27%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="35%" colspan="8"&gt;  &lt;div&gt;June&amp;#160;30,&amp;#160;2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="35%" colspan="8"&gt;  &lt;div&gt;December&amp;#160;31,&amp;#160;2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="27%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Current&lt;br/&gt;   portion,&amp;#160;net&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Non-&lt;br/&gt;   current&lt;br/&gt;   portion,&amp;#160;net&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Total&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Current&lt;br/&gt;   portion,&amp;#160;net&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Non-&lt;br/&gt;   current&lt;br/&gt;   portion,&amp;#160;net&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Total&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="27%"&gt;  &lt;div&gt;Convertible 5% Notes Payable&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;-&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,364,816&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,364,816&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;-&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,479,098&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,479,098&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="27%"&gt;  &lt;div&gt;ICON Convertible Note&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;677,778&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;-&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;677,778&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;677,778&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;-&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;677,778&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="27%"&gt;  &lt;div&gt;Total&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;677,778&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,364,816&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;3,042,594&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;677,778&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,479,098&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;3,156,876&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt;  &lt;/div&gt;  &lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  We assumed the preceding notes payable as the result of the  Exchange Transaction between the Company and TG Bio. Accordingly, a  valuation using the guidance in the accounting literature for  business combinations (ASC 805) was performed and these notes have  been presented at their fair value on the date of the  transaction.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;&lt;em&gt;Convertible 5% Notes Payable&lt;/em&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  On March 8, 2010, Manhattan entered into an Agreement and Plan of  Merger (the "Merger Agreement") by and among Manhattan, Ariston  Pharmaceuticals, Inc., a Delaware corporation ("Ariston") and  Ariston Merger Corp., a Delaware corporation and wholly-owned  subsidiary of Manhattan (the "Merger Sub").&amp;#160; Pursuant to the  terms and conditions set forth in the Merger Agreement, on March 8,  2010, the Merger Sub merged with and into Ariston (the "Merger"),  with Ariston being the surviving corporation of the Merger.&amp;#160;  As a result of the Merger, Ariston became a wholly-owned subsidiary  of Manhattan.&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  The 5% Notes and accrued and unpaid interest thereon are  convertible at the option of the holder into Common Stock at the  conversion price of $&lt;font style=" FONT-SIZE: 10pt"&gt;1,125&lt;/font&gt;  per share.&amp;#160;&amp;#160;Ariston agreed to make quarterly payments on  the &lt;font style=" FONT-SIZE: 10pt"&gt;5&lt;/font&gt;% Notes equal to &lt;font  style=" FONT-SIZE: 10pt"&gt;50&lt;/font&gt;% of the net product cash flow  received from the exploitation or commercialization of  Ariston&amp;#8217;s product candidates, AST-726 and  AST-915.&amp;#160;&amp;#160;&lt;font style="BACKGROUND-COLOR: transparent; COLOR: black"&gt;The Company has no  obligations under the 5% Notes aside from a) 50% of the net product  cash flows from Ariston&amp;#8217;s product candidates, if any, payable  to noteholders; and b) the conversion feature, discussed  above.&lt;/font&gt; Interest accrues monthly, is added to principal on an  annual basis, every March 8, and is payable at maturity.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  In connection with the Exchange Transaction in December 2011, the  Company performed a valuation of the assets and liabilities of  Manhattan immediately prior to the transaction. &lt;font style="BACKGROUND-COLOR: transparent; COLOR: black"&gt;The cumulative  liability including accrued and unpaid interest of these notes was  approximately $&lt;font style=" FONT-SIZE: 10pt"&gt;16,876,000&lt;/font&gt;  immediately prior to the Exchange Transaction, $&lt;font style=" FONT-SIZE: 10pt"&gt;17,727,000&lt;/font&gt; at December 31, 2012 and  $&lt;/font&gt;&lt;font style=" FONT-SIZE: 10pt"&gt;18,167,000&lt;/font&gt; &lt;font  style="BACKGROUND-COLOR: transparent; COLOR: black"&gt;at June 30,  2013.&lt;/font&gt; As these notes payable are tied directly to net  product cash flows derived from the preexisting products of the  Company, this note and accrued interest was recorded at fair value  as of the date of the Exchange Transaction. No payments have been  made on these notes as of June 30, 2013. See Note 2 for further  details.&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;&lt;em&gt;ICON Convertible Note Payable&lt;/em&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  In connection with the merger with Ariston as discussed above,  Ariston satisfied an account payable of $&lt;font style=" FONT-SIZE: 10pt"&gt;1,275,188&lt;/font&gt; to ICON Clinical Research  Limited (&amp;#8220;ICON&amp;#8221;) through the payment of $&lt;font style=" FONT-SIZE: 10pt"&gt;275,188&lt;/font&gt; in cash and the issuance of a  three-year 5% note payable (the &amp;#8220;ICON  Note&amp;#8221;).&amp;#160;&amp;#160;The principal was to be repaid in &lt;font  style=" FONT-SIZE: 10pt"&gt;36 month&lt;/font&gt;ly installments of $&lt;font  style=" FONT-SIZE: 10pt"&gt;27,778&lt;/font&gt; commencing in April  2010.&amp;#160;&amp;#160;Interest was payable monthly in arrears.  &amp;#160;&amp;#160;On March 1, 2011, Ariston entered into an amended and  restated convertible promissory note (the &amp;#8220;Amended ICON  Note&amp;#8221;) with ICON. The principal terms of the Amended ICON  Note are that monthly payments of principal and interest will be  waived for the thirteen month period ended December 31, 2011 (the  &amp;#8220;Waiver Period&amp;#8221;) in exchange for a single payment of  $&lt;font style=" FONT-SIZE: 10pt"&gt;100,000&lt;/font&gt; on March 31, 2011,  an increase in the interest on the Amended ICON Note from &lt;font  style=" FONT-SIZE: 10pt"&gt;5&lt;/font&gt;% to &lt;font style=" FONT-SIZE: 10pt"&gt;8&lt;/font&gt;% per annum during the Waiver Period and  a balloon payment on January 31, 2012. The Amended ICON Note is  convertible at the option of the holder into the Company&amp;#8217;s  Common Stock at the conversion price of $&lt;font style=" FONT-SIZE: 10pt"&gt;562.50&lt;/font&gt; per share. During the six months  ended June 30, 2013, the Company recorded $&lt;font style=" FONT-SIZE: 10pt"&gt;32,318&lt;/font&gt; of interest expense on the Amended  ICON Note. At June 30, 2013, the principal amount of the Amended  ICON Note was $&lt;font style=" FONT-SIZE: 10pt"&gt;677,778&lt;/font&gt;, of  which the entire balance has been classified as current, and  interest payable on the Amended ICON Note was $&lt;font style=" FONT-SIZE: 10pt"&gt;155,829&lt;/font&gt;. This note is currently in  default as the Company did not make the balloon payment due on  January 31, 2012, or any subsequent payments. The Company is  currently attempting to negotiate a settlement or alternative  arrangement in satisfaction of this note.&lt;/div&gt;  &lt;/div&gt;        </us-gaap:DebtDisclosureTextBlock>

  <us-gaap:ScheduleOfDebtTableTextBlock contextRef="P01_01_2013To06_30_2013" id="Factid_418">              &lt;table border="0" style="clear:both;width:100%; table-layout:fixed;"&gt;  &lt;tr&gt;  &lt;td&gt;&lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  The following is a summary of notes payable:&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; FONT-SIZE: 10pt"&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="clear:both;BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="27%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="35%" colspan="8"&gt;  &lt;div&gt;June&amp;#160;30,&amp;#160;2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="35%" colspan="8"&gt;  &lt;div&gt;December&amp;#160;31,&amp;#160;2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="27%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Current&lt;br/&gt;   portion,&amp;#160;net&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Non-&lt;br/&gt;   current&lt;br/&gt;   portion,&amp;#160;net&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Total&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Current&lt;br/&gt;   portion,&amp;#160;net&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Non-&lt;br/&gt;   current&lt;br/&gt;   portion,&amp;#160;net&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Total&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="27%"&gt;  &lt;div&gt;Convertible 5% Notes Payable&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;-&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,364,816&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,364,816&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;-&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,479,098&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,479,098&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="27%"&gt;  &lt;div&gt;ICON Convertible Note&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;677,778&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;-&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;677,778&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;677,778&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;-&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;677,778&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="27%"&gt;  &lt;div&gt;Total&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;677,778&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,364,816&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;3,042,594&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;677,778&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,479,098&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;3,156,876&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt;  &lt;/div&gt;  &lt;/div&gt;  &lt;/div&gt;        </us-gaap:ScheduleOfDebtTableTextBlock>

  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="PAsOn03_08_2010_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis" id="Factid_419" unitRef="USD_per_Share" decimals="0">1125</us-gaap:DebtInstrumentConvertibleConversionPrice1>

  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="PAsOn03_08_2010_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis" id="Factid_420" unitRef="pure" decimals="2">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>

  <tgtx:PercentageOfCashProceedsFromOperationToRepayInterestOnConvertibleDebt contextRef="P03_01_2010To03_08_2010_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis" id="Factid_421" unitRef="pure" decimals="1">0.5</tgtx:PercentageOfCashProceedsFromOperationToRepayInterestOnConvertibleDebt>

  <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="PAsOn03_08_2010_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis" id="Factid_422" unitRef="USD" decimals="0">1275188</us-gaap:AccountsPayableCurrentAndNoncurrent>

  <us-gaap:RepaymentsOfShortTermDebt contextRef="P03_01_2010To03_08_2010_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis" id="Factid_423" unitRef="USD" decimals="0">275188</us-gaap:RepaymentsOfShortTermDebt>

  <us-gaap:DebtInstrumentPeriodicPaymentPrincipal contextRef="P03_01_2010To03_08_2010_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis" id="Factid_424" unitRef="USD" decimals="0">27778</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>

  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="PAsOn03_31_2011_AfterAmendmentMembertgtxAmendmentAxis_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis" id="Factid_425" unitRef="pure" decimals="2">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>

  <tgtx:DebtInstrumentRepaymentTerm contextRef="P03_01_2010To03_08_2010_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis" id="Factid_426">36 month</tgtx:DebtInstrumentRepaymentTerm>

  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="PAsOn03_31_2011_BeforeAmendmentMembertgtxAmendmentAxis_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis" id="Factid_427" unitRef="pure" decimals="2">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>

  <tgtx:OneTimeSettlementAmountForWaiverOfInterestAndPrincipalPayments contextRef="PAsOn03_31_2011_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis" id="Factid_428" unitRef="USD" decimals="0">100000</tgtx:OneTimeSettlementAmountForWaiverOfInterestAndPrincipalPayments>

  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="PAsOn03_31_2011_AfterAmendmentMembertgtxAmendmentAxis_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis" id="Factid_429" unitRef="USD_per_Share" decimals="2">562.50</us-gaap:DebtInstrumentConvertibleConversionPrice1>

  <us-gaap:InterestAndDebtExpense contextRef="P01_01_2013To06_30_2013_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis" id="Factid_430" unitRef="USD" decimals="0">32318</us-gaap:InterestAndDebtExpense>

  <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="PAsOn06_30_2013_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis" id="Factid_431" unitRef="USD" decimals="0">155829</us-gaap:InterestPayableCurrentAndNoncurrent>

  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="PAsOn06_30_2013" id="Factid_432" unitRef="pure" decimals="2">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>

  <us-gaap:NotesPayableCurrent contextRef="PAsOn06_30_2013_ConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis" id="Factid_433" unitRef="USD" decimals="0">0</us-gaap:NotesPayableCurrent>

  <us-gaap:NotesPayableCurrent contextRef="PAsOn06_30_2013_IconConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis" id="Factid_434" unitRef="USD" decimals="0">677778</us-gaap:NotesPayableCurrent>

  <us-gaap:LongTermNotesPayable contextRef="PAsOn06_30_2013_ConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis" id="Factid_435" unitRef="USD" decimals="0">2364816</us-gaap:LongTermNotesPayable>

  <us-gaap:LongTermNotesPayable contextRef="PAsOn06_30_2013_IconConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis" id="Factid_436" unitRef="USD" decimals="0">0</us-gaap:LongTermNotesPayable>

  <us-gaap:LongTermNotesPayable contextRef="PAsOn12_31_2012_ConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis" id="Factid_437" unitRef="USD" decimals="0">2479098</us-gaap:LongTermNotesPayable>

  <us-gaap:LongTermNotesPayable contextRef="PAsOn12_31_2012_IconConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis" id="Factid_438" unitRef="USD" decimals="0">0</us-gaap:LongTermNotesPayable>

  <us-gaap:NotesPayable contextRef="PAsOn06_30_2013" id="Factid_439" unitRef="USD" decimals="0">3042594</us-gaap:NotesPayable>

  <us-gaap:NotesPayable contextRef="PAsOn12_31_2012" id="Factid_440" unitRef="USD" decimals="0">3156876</us-gaap:NotesPayable>

  <us-gaap:NotesPayable contextRef="PAsOn06_30_2013_ConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis" id="Factid_441" unitRef="USD" decimals="0">2364816</us-gaap:NotesPayable>

  <us-gaap:NotesPayable contextRef="PAsOn06_30_2013_IconConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis" id="Factid_442" unitRef="USD" decimals="0">677778</us-gaap:NotesPayable>

  <us-gaap:NotesPayable contextRef="PAsOn12_31_2012_ConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis" id="Factid_443" unitRef="USD" decimals="0">2479098</us-gaap:NotesPayable>

  <us-gaap:NotesPayable contextRef="PAsOn12_31_2012_IconConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis" id="Factid_444" unitRef="USD" decimals="0">677778</us-gaap:NotesPayable>

  <us-gaap:NotesPayableCurrent contextRef="PAsOn12_31_2012_ConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis" id="Factid_445" unitRef="USD" decimals="0">0</us-gaap:NotesPayableCurrent>

  <us-gaap:NotesPayableCurrent contextRef="PAsOn12_31_2012_IconConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis" id="Factid_446" unitRef="USD" decimals="0">677778</us-gaap:NotesPayableCurrent>

  <tgtx:LicenseAgreementDisclosureTextBlock contextRef="P01_01_2013To06_30_2013" id="Factid_447">              &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;b&gt;NOTE 5 &amp;#150; LICENSE AGREEMENTS&lt;/b&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  In November 2012, we entered into an exclusive (within the  territory) sublicense agreement with Ildong Pharmaceutical Co. Ltd,  (&amp;#8220;Ildong&amp;#8221;) relating to the development and  commercialization of TG-1101 in South Korea and Southeast Asia.  Under the terms of the sublicense agreement, Ildong has been  granted a royalty bearing, exclusive right, including the right to  grant sublicenses, to develop and commercialize&amp;#160;TG-1101 in  South Korea, Taiwan, Singapore, Indonesia, Malaysia, Thailand,  Philippines, Vietnam, and Myanmar.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;font style="COLOR: black"&gt;An upfront payment of $&lt;font style=" FONT-SIZE: 10pt"&gt;2,000,000&lt;/font&gt;, which was received in December  2012 net of $&lt;font style=" FONT-SIZE: 10pt"&gt;330,000&lt;/font&gt; of  foreign income tax withheld, is being recognized as license revenue  on a straight-line basis over the life of the agreement, which is  through the expiration of the last licensed patent right or 15  years after the first commercial sale of a product in such country,  unless the agreement is earlier terminated.&lt;/font&gt; The upfront  payment will be recognized as license revenue on a straight-line  basis through December 2025, which represents the estimated period  over which the Company will have certain ongoing responsibilities  under the sublicense agreement. &lt;font style="COLOR: black"&gt;The  Company recorded license revenue of approximately $&lt;font style=" FONT-SIZE: 10pt"&gt;76,000&lt;/font&gt; for the six months ended June 30,  2013, and has deferred revenue of approximately $&lt;font style=" FONT-SIZE: 10pt"&gt;1,905,000&lt;/font&gt; associated with this $2,000,000  payment (approximately $&lt;font style=" FONT-SIZE: 10pt"&gt;152,000&lt;/font&gt; of which has been classified as a  current liability) at June 30, 2013.&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  The Company may receive up to an additional $&lt;font style=" FONT-SIZE: 10pt"&gt;5.0&lt;/font&gt; million in payments upon the  achievement of pre-specified milestones. In addition, upon  commercialization, Ildong will make royalty payments to the Company  on net sales of TG-1101 in the sublicense territory.&lt;/div&gt;  &lt;/div&gt;        </tgtx:LicenseAgreementDisclosureTextBlock>

  <tgtx:UpfrontLicensesRevenuePaymentReceived contextRef="P01_01_2012To12_31_2012" id="Factid_448" unitRef="USD" decimals="0">2000000</tgtx:UpfrontLicensesRevenuePaymentReceived>

  <us-gaap:IncomeTaxExpenseBenefit contextRef="P01_01_2012To12_31_2012" id="Factid_449" unitRef="USD" decimals="0">330000</us-gaap:IncomeTaxExpenseBenefit>

  <us-gaap:DeferredRevenue contextRef="PAsOn06_30_2013" id="Factid_450" unitRef="USD" decimals="0">1905000</us-gaap:DeferredRevenue>

  <tgtx:AdditionalAmountReceivableOnAchievementOfPreSpecifiedMilestones contextRef="P01_01_2013To06_30_2013" id="Factid_451" unitRef="USD" decimals="-5">5000000</tgtx:AdditionalAmountReceivableOnAchievementOfPreSpecifiedMilestones>

  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2013To06_30_2013" id="Factid_452">              &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;NOTE 6 &amp;#150; RELATED PARTY TRANSACTIONS&lt;/strong&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;&amp;#160;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  On January 30, 2012, the Company entered into an exclusive license  agreement with LFB Biotechnologies, GTC Biotherapeutics and LFB/GTC  LLC, all wholly-owned subsidiaries of LFB Group, relating to the  development of&amp;#160;TG-1101 (the &amp;#8220;License Agreement&amp;#8221;).  In connection with the License Agreement, LFB Group was issued  &lt;font style=" FONT-SIZE: 10pt"&gt;5,000,000&lt;/font&gt; shares of Company  Common Stock and a warrant to purchase &lt;font style=" FONT-SIZE: 10pt"&gt;2,500,000&lt;/font&gt; shares of Company Common stock  at a purchase price of $&lt;font style=" FONT-SIZE: 10pt"&gt;0.001&lt;/font&gt;  per share. In addition, on November 9, 2012, the Company nominated  Dr. Yann Echelard to the Company&amp;#8217;s Board of Directors as LFB  Group&amp;#8217;s nominee. LFB Group maintains the right to nominate a  board member until such time as LFB Group owns less than 10% of the  outstanding Company Common Stock.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  Under the terms of the Company&amp;#8217;s License Agreement with LFB  Group, the Company utilizes LFB Group for certain development and  manufacturing services. The Company incurred approximately $&lt;font  style=" FONT-SIZE: 10pt"&gt;4,035,000&lt;/font&gt; in such expenses during  the six months ended June 30, 2013, which have been included in  other research and development expenses in the accompanying  condensed consolidated statements of operations. As of June 30,  2013, the Company has approximately $&lt;font style=" FONT-SIZE: 10pt"&gt;1,476,000&lt;/font&gt; recorded in accounts payable  related to the aforementioned agreements with LFB Group. In  conjunction with the development and manufacturing services  discussed above, certain agreements between the Company and LFB  Group require payments in advance of services performed or goods  delivered. Accordingly, as of June 30, 2013, the Company recorded  approximately $&lt;font style=" FONT-SIZE: 10pt"&gt;429,957&lt;/font&gt; in  prepaid research and development for such advance payments.&lt;/div&gt;  &lt;/div&gt;        </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P01_01_2012To01_30_2012_LfbGroupMembertgtxPlacementAgencyAgreementAxis" id="Factid_453" unitRef="shares" decimals="INF">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <tgtx:NumberOfCommonStockSharesGrantedInConnectionWithLicenseAgreementByIssueOfWarrants contextRef="P01_01_2012To01_30_2012_LfbGroupMembertgtxPlacementAgencyAgreementAxis" id="Factid_454" unitRef="shares" decimals="INF">2500000</tgtx:NumberOfCommonStockSharesGrantedInConnectionWithLicenseAgreementByIssueOfWarrants>

  <tgtx:OtherResearchAndDevelopment contextRef="P01_01_2013To06_30_2013_LfbGroupMembertgtxPlacementAgencyAgreementAxis" id="Factid_455" unitRef="USD" decimals="0">4035000</tgtx:OtherResearchAndDevelopment>

  <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="PAsOn06_30_2013_LfbGroupMembertgtxPlacementAgencyAgreementAxis" id="Factid_456" unitRef="USD" decimals="0">1476000</us-gaap:AccountsPayableCurrentAndNoncurrent>

  <tgtx:PrepaidResearchAndDevelopment contextRef="PAsOn06_30_2013_ResearchDevelopmentExpensesMembertgtxResearchDevelopmentExpensesAxis" id="Factid_457" unitRef="USD" decimals="0">429957</tgtx:PrepaidResearchAndDevelopment>

  <tgtx:CommonStockPurchasePricePerShare contextRef="PAsOn01_30_2012_LfbGroupMembertgtxPlacementAgencyAgreementAxis" id="Factid_458" unitRef="USD_per_Share" decimals="3">0.001</tgtx:CommonStockPurchasePricePerShare>

  <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2013To06_30_2013" id="Factid_459">              &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;NOTE 7 &amp;#150; SUBSEQUENT EVENTS&lt;/strong&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  On July 18, 2013, we announced the pricing of an underwritten  public offering of &lt;font style=" FONT-SIZE: 10pt"&gt;5,700,000&lt;/font&gt;  shares of our common stock at a price of $&lt;font style=" FONT-SIZE: 10pt"&gt;6.15&lt;/font&gt; per share for gross proceeds of  approximately $&lt;font style=" FONT-SIZE: 10pt"&gt;35&lt;/font&gt; million. We  also granted to the underwriters a 30-day option to acquire an  additional &lt;font style=" FONT-SIZE: 10pt"&gt;855,000&lt;/font&gt; shares to  cover overallotments in connection with the offering. Total net  proceeds from this offering, including the overallotment, were  approximately $&lt;font style=" FONT-SIZE: 10pt"&gt;37.4&lt;/font&gt; million,  net of underwriting discounts and estimated offering expenses of  approximately $&lt;font style=" FONT-SIZE: 10pt"&gt;2.9&lt;/font&gt; million.  The shares were sold under a shelf registration statement on Form  S-3 (File No. 333-189015) that was previously filed and declared  effective by the SEC on June 17, 2013.&lt;/div&gt;  &lt;/div&gt;        </us-gaap:SubsequentEventsTextBlock>

<!--FootNote Section Ref-->

  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
  </link:footnoteLink>
</xbrli:xbrl>

